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Abstract
The P2X7 receptor is a ligand-gated ion channel present on normal and
malignant cells of hematopoietic and epithelial origins. Activation of the P2X7 receptor
by extracellular adenosine 5’-triphosphate (ATP) causes the rapid flux of Na+, K+ and
Ca2+. Continued activation of P2X7 allows the formation of large, non-specific pores,
allowing the uptake of organic molecules including cation dyes. In addition, activation
of P2X7 leads to a number of downstream signalling events which includes the
maturation and release of interlukin (IL)-1β, as well as cell proliferation and death. As a
result of these latter roles of P2X7 in cell survival, this receptor is attracting
considerable interest for its growth-promoting and growth-inhibitory roles in cancer.
Therefore, the aim of this project was to study the expression and function of the P2X7
receptor in myeloid leukemic and epithelial malignant cancer cell lines.
Previous work in our laboratory demonstrated that the immunomodulatory
cytokine, transforming growth factor (TGF)-β1 prevents the up-regulation of P2X7 in
the human myeloid leukemic cell line, THP-1 by interferon (IFN)-γ and
lipopolysaccharide (LPS). The mechanism of action of TGF-β1 in this process however
was never elucidated. Therefore, the first part of my study aimed to determine the
mechanism of action of TGF-β1 on the up-regulation of P2X7 expression and function
in THP-1 cells differentiated with IFN-γ and LPS. Cell-surface molecules including
P2X7 were examined by immunofluorescence staining. Total P2X7 protein and mRNA
was assessed by immunoblotting and RT-PCR respectively. P2X7 function was
evaluated by ATP-induced cation dye uptake measurements. IL-1β release was
measured by ELISA. Cell-surface P2X7 was present on THP-1 cells differentiated for 3
days with IFN-γ and LPS but not on undifferentiated THP-1 cells. Similarly, ATP
13

induced ethidium+ uptake into differentiated but not undifferentiated THP-1 cells. Coincubation of cells with TGF-β1 plus IFN-γ and LPS prevented the up-regulation of
P2X7 expression and ATP-induced ethidium+ uptake Moreover, ATP-induced YOPRO-12+ uptake and IL-1β release were abrogated in IFN-γ and LPS-treated cells coincubated with TGF-β1. Of note, TGF-β1 abrogated the amount of total P2X7 protein
and mRNA induced by IFN-γ and LPS. Finally, TGF-β1 prevented the up-regulation of
cell-surface CD86, but not other differentiation markers (CD14 and MHC class II), by
IFN-γ and LPS. Collectively, these results indicate that TGF-β1 prevents the upregulation of P2X7 by IFN-γ and LPS in THP-1 monocytes by preventing P2X7
transcription and subsequent translation. Moreover, this effect of TGF-β1 is not due to
general impairment of THP-1 cell differentiation by IFN-γ and LPS. This suggests that
TGF-β1 may limit P2X7-mediated processes during inflammation and immunity, as
well as in cancer cells.
Previous work by others has indicated that ATP and 2(3’)-O-(4-benzoylbenzoyl)
adenosine 5’-triphosphate (BzATP) induces the death of the human epithelial colon
carcinoma cell lines, HCT-8 and Caco-2 in a manner characteristic of P2X7 activation.
However a direct role for this receptor in this process was not established. Therefore,
the second part of my study aimed to determine if HCT-8 and Caco-2 cells expressed
functional P2X7. Cell-surface and total P2X7 was examined by immunofluorescence
staining and immunoblotting respectively. P2X7 function was evaluated by ATP- and
BzATP-induced ethidium+ uptake measurements. Reduction in cell numbers, as an
indirect measure of cell death, was evaluated using a tetrazolium-based colorimetric
assay. The human multiple myeloma cell line, RPMI 8226, was used as a positive
control. HCT-8 and Caco-2 cells expressed low levels of cell-surface P2X7. Whole
14

lysates of these cells expressed low levels of the full length (75 kDa) P2X7, but higher
levels of a 42 kDa P2X7 variant. In contrast, RPMI 8226 cells expressed relatively high
levels of cell-surface P2X7, as well as full-length P2X7. ATP and BzATP consistently
failed to induce ethidium+ uptake in HCT-8 and Caco-2 despite extended incubation
times of up to 30 min, and the use of several media known to potentiate P2X7 activation.
ATP and BzATP also failed to cause significant death in both the cell lines. In contrast,
ATP and BzATP induced ethidium+ uptake and death in RPMI 8226 cells. IFN-γ failed
to upregulate P2X7 expression and function in HCT-8 cells. Collectively, these results
indicate the absence of functional P2X7 in HCT-8 and Caco-2 cells despite the presence
of low levels of cell-surface P2X7. The high proportion of a 42 kDa P2X7 variant
provides a possible explanation for the lack of functional P2X7 in these cells.
The presence of functional P2X7 in primary myeloid leukemias has been
reported by others; however cell line models of myeloid leukemia that constitutively
expresses functional P2X7 are limited. Therefore, the final part of my study aimed to
determine if the human myeloid leukemic cell line KG-1 expresses functional P2X7.
Cell-surface P2X7 was examined by immunofluorescence staining. Total P2X7 protein
and mRNA was assessed by immunoblotting and RT-PCR respectively. P2X7 function
was evaluated by ATP-induced ethidium+ uptake measurements. Reduction in cell
numbers was evaluated using a tetrazolium-based colorimetric assay and cell death was
confirmed using a trypan blue exclusion assay and morphological analysis. KG-1 cells
expressed low levels of cell-surface P2X7, as well as low levels of P2X7 protein and
mRNA. Both, ATP and BzATP consistently induced ethidium+ uptake in KCl and
sucrose but not NaCl medium. ATP-induced ethidium+ uptake in a concentration
dependant manner with a maximal response at 100 µM and with an EC50 of 8.5 µM
15

which is ~ 10 fold lower than that reported for recombinant P2X7-induced cation fluxes.
Moreover, the non-P2X7 agonist, α-β-methyl adenosine 5’-triphosphate (αβmeATP), as
well as ATP, BzATP and adenosine 5'-O-[3-thiotriphosphate] (ATP-γ-S) induced
ethidium+ uptake in KG-1 cells. The P2X7 antagonists, KN-62, AZ10606120 and A438079, each impaired ATP-induced ethidium+ uptake. ATP induced KG-1 cell death
and morphological analysis indicated that this process was characteristic of apoptosis.
ATP-induced apoptosis was impaired by KN-62 and AZ10606120. Collectively, these
results indicate that KG-1 cells express functional P2X7 with an atypical
pharmacological profile.
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Chapter 1: Introduction
1.1 Purinergic Signalling
Adenosine 5’-triphosphate (ATP) is the main source of free intracellular energy
in cells; however it is now widely accepted that ATP also functions as an extracellular
signalling molecule. The role of ATP as an extracellular signalling molecule was first
established by Burnstock (1972) in neurotransmission which gave rise to the term
purinergic signalling. ATP is secreted into the extracellular environment under
conditions of tissue stress, inflammation or, infection or during neurotransmitter release
to function in an autocrine or paracrine fashion (Lazarowski et al., 2003). In the
extracellular environment, ATP activates a group of cell-surface nucleotide or
purinergic receptors, called P2X and P2Y receptors.
The P2X purinergic receptors are a trimeric, ligand-gated cation channels, which
upon activation by ATP allows the influx of Na+ and Ca2+ ions, and an efflux of K+.
Seven subtypes of P2X subunits (P2X1-P2X7) have been cloned (North, 2002). P2Y
receptors are G-protein-coupled metabotropic receptors, activated by ATP, ADP,
uridine 5’-diphosphate (UDP) and uridine 5’-triphosphate (UTP). Eight P2Y receptor
subtypes have been cloned (P2Y1, P2Y2, P2Y4, P2Y6, P2Y11, P2Y12, P2Y13 and
P2Y14) (von Kugelgen, 2006). The role of P2X and P2Y receptors in physiology is
gaining importance as they are widely distributed on a large array of cell types and
induce important events in cells including proliferation, differentiation, apoptosis or
necrosis, and release of inflammatory and tissue regenerating molecules. However the
precise mechanisms of these receptors are yet to be fully characterised (Burnstock,
2007).
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1.2 The P2X7 Receptor
1.2.1 P2X7 subunit
The P2X7 subunit is a 595 amino acid sequence consisting of an intracellular Nterminus, two hydrophobic transmembrane domains, an extracellular loop and an
intracellular C-terminus (North, 2002) (Fig.1). The N- and C-termini of P2X7 comprise
amino acids 1-25 and 356-595 respectively and form intracellular complexes with
several membrane proteins including α-actin, receptor-like tyrosine phosphatase and
heat shock proteins (Kim et al., 2001). In addition, the C-terminus is essential for pore
formation and receptor trafficking (Smart et al., 2003; Suprenant et al., 1996). It has
also shown to stabilize the expression of P2X7 receptor in the membrane (Boldt et al.,
2003; Denlinger et al., 2003; Feng et al., 2006). The first and second transmembrane
domains comprise amino acids 26-46 and 335-355 repectively. The extracellular loop
(amino acids 47- 334) comprises the main binding site of ATP (North, 2002) and also
contains five N-glycosylation sites (Zhou et al., 2009), of which Asn , Asn and Asn
187

213

241

have been proposed to contribute towards P2X7 function (Feng et al., 2006; Gorodeski,
2009). The P2X7 subunits are assembled as a trimeric molecule to form functional
P2X7 receptors (Nicke, 2008).
1.2.2 P2X7 pore formation
The activation of the P2X7 receptor by ATP or the most potent P2X7 agonist,
2(3’)-O-(4-benzoylbenzoyl) adenosine 5’-triphosphate (BzATP) causes a rapid influx of
Ca2+ and Na+, and an efflux of K+ by the opening of a non-selective cation channel,
which is similar to that observed in other P2X receptors. However, the P2X7 receptor is
a unique member of the P2X family in that, prolonged exposure to its agonists causes
the formation of a pore permeable to organic molecules up to 900 Da in size (Burnstock,
18

2007). Fluorescent dyes such as ethidium+ (314 Da) and YO-PRO-12+ (375 Da) are
routinely used to assay the pore properties of this receptor (Burnstock, 2007). Initially it
was implied that the dye uptake took place via the ion channel that dilated into the pore
over prolonged exposure to the agonist (North, 2002). More recent evidence however
suggests the activation of a distinct hemichannel, pannexin-1, and subsequent
interaction with P2X7 to form the dye uptake pathway (Pelegrin and Suprenant, 2006).
Pannexins are a three-member family (pannexin 1-3) of mammalian membrane proteins
that form gap-junction like connections, thus it remains unclear how pannexin-1 allows
the intracellular passage of organic dyes (Pelegrin and Suprenant, 2006). Pannexin-1
also appears to be essential for the P2X7-induced maturation and release of interlukin
(IL)-1β from macrophages (Pelegrin and Suprenant, 2006). However the role of
pannexin-1 in P2X7 pore formation is still controversial and requires verification by
others.

Fig.1.1 Schematic representation of the P2X7 subunit. The P2X7 protein is a 595 amino
acid sequence consisting of an intracellular N-terminus (blue), two hydrophobic
transmembrane domains (green), an extracellular loop (black) and an intracellular Cterminus (red). Adapted from Kim et al (2001)
19

1.2.3 P2X7 polymorphims
The human P2RX7 gene is localized in a 55-kb region of chromosome 12q34
and comprises 13 exons (Buell et al., 1998). The P2RX7 gene is highly polymorphic
with more than 686 single-nucleotide polymorphisms (SNPs) (Sun et al., 2010).
However, the functional effects of most SNPs are unclear. Most of the SNPs (G150R,
R307Q, T357S, E496A, and I568N) characterised to date have been shown to cause
loss-of-function (Gu et al., 2001, 2004; Shemon et al., 2006 Stokes et al., 2010; Wiley
et al., 2003). Cabrini et al. (2005) identified the first gain-of-function SNP (H155Y).
Other gain-of-function SNPs (A166G and A348T) have also been described (Denlinger
et al., 2006; Stokes et al., 2010; Sun et al., 2010). Genetic studies have implicated the
E496A SNP with increased susceptibility to chronic lymphocytic leukemia and
tuberculosis (Fernando et al., 2007; Saunders et al., 2003; Wiley et al., 2002; Dao-Ung
et al., 2004). The Q460R SNP has been associated with increased susceptibility to
unipolar and bipolar mood disorders (Barden et al., 2006; Macquillin et al., 2008);
however this SNP does not alter function (Fuller et al., 2009). Stokes et al (2010)
identified five variants of a 4-SNP haplotype block located within exons 11 to 13 of the
human P2RX7 gene. Of note, the P2X7-4 variant contained both the Q460R and A348T
SNPs suggesting that the association of the Q460R with the gain-of-function A348T
SNP may account for the association of Q460R with mood disorders (Stokes et al.,
2010). These findings suggest that future genetic association studies of P2X7 SNPs and
disease should consider P2RX7 haplotypes rather than single SNPs.
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1.2.4 Splice variants of P2X7
P2X7 function involves the tri-oligomerization of the full-length receptor,
influenced by the presence of monomer units and truncated variants of the P2X7
receptor (Le et al,. 1998; Lewis et al,. 1995; MacKenzie et al,. 1999; Torres et al,. 1999;
Virginio et al,. 1998). A P2X7 splice variant, in which the transmembrane 1 is deleted,
does

not

generate

functional

receptors

upon

heterologous

expression

(Cheewatrakoolpong et al., 2005), whereas deletion of the cytoplasmic tail prevents dye
uptake and pro-apoptotic effects (Suprenant et al., 1996). Nine truncated variants of the
human P2X7 receptor (P2X7-b to P2X7-j) via alternative splicing were originally
identified (Cheewatrakoolpong et al., 2005; Feng et al., 2006). Only one, the P2X7-b
variant, out of the nine variants was found to be partially functional. This variant,
expressed in most human tissues, was found to contain P2X7 channel but not pore
activity (Cheewatrakoolpong et al., 2005). Whether the P2X7-b variant interacts with
the full-length P2X7 to form heteromeric channels remains unknown. In contrast, the
P2X7-j variant is found in malignant epithelial cells, hetero-oligomerizes with fulllength P2X7 to form P2X7 heteromers that completely lack channel or pore activity,
and fail to mediate P2X7-mediated apoptosis (Feng et al., 2006). The P2X7-j variant
lacks the distal third of the extracellular loop, the second transmembrane domain, and
the entire C-terminus (Feng et al., 2006). Recently, Nicke et al (2009) identified and
characterised a novel P2X7 variant, P2X7-k, highly expressed in rodent liver and spleen.
This variant has an alternative N-terminus and transmembrane domain 1 and has an 8fold higher sensitivity to BzATP compared to the wild-type P2X7 (P2X7-a) and high
levels of organic cation uptake. A greater understanding of this variant will provide a
valuable tool in elucidating the mechanism involved in P2X7-mediated pore formation.
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1.2.5 P2X7/P2X4 heteromers
Structural and functional interactions between the P2X7 and P2X4 receptors has
gained much interest since the P2X4 receptor is nearly 40% more homologous to the
P2X7 receptor than other P2X receptors, and the P2RX4 gene is located 130 kb
downstream of the P2RX7 gene (Buell et al., 1998). The P2X7/P2X4 heterotrimer has
been reportedly found in macrophages, monocytes, microglia, and endothelial and
epithelial cells (Guo et al., 2007). However, Nicke (2008) showed that heterotrimerization of the P2X7 and P2X4 receptors results in unstable complexes and thus
P2X7/P2X4 heteromers are unlikely to form a dominant subtype in tissues.
1.2.6 P2X7 Agonists
Each P2X receptor displays a unique pharmacological profile (Table 1). The
P2X7 receptor is distinct from the other P2X members requiring 10- to 100-fold higher
ATP concentrations for its activation compared to other P2X receptors (North and
Suprenant, 2000). The half-effective concentration (EC50) of ATP required to activate
the P2X7 receptor is ~100 µM, with maximal activation obtained at 300 µM ATP
(North and Suprenant, 2000). The ATP analog, BzATP, is 10-30 times more potent than
ATP in activating P2X7, although BzATP is not specific to P2X7 as it also activates
P2X1 and P2X3 (North, 2002). Agonist potency at the P2X7 receptor is ranked in order
of BzATP > ATP >> 2-methylthioadenosine 5’-triphosphate (2MeSATP) > adenosine
5’-O-(3-thio) triphosphate (ATPγS) >>> αβ-methylene adenosine 5’-triphosphate
(αβmeATP) > ADP > UTP (Suprenant et al., 1996). The presence of µM concentrations
of ATP has not been observed in vivo, but data with P2X7 knock-out indicate that ATP
can be released to activate P2X7 in vivo at least under particular pathophysiological
conditions (Labasi et al., 2002; Chessel et al, 2005).
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1.2.7 P2X7 Antagonists
A number of specific P2X7 antagonists are now commonly available. The
isoquinoline sulfonamide 1-[N,O-bis(5-isoquinolinesulfonyl)-N-methyl-L-tyrosyl]-4phenylpiperazine (KN-62), is a potent, non-competitive, human P2X7 antagonist
(Gargett and Wiley, 1997) which has been used for more than a decade. KN-62 however
also inhibits calmodulin-dependant protein kinase II (Chessell et al., 1998) complicating
its use when studying events downstream of P2X7 activation. KN-62 is inactive at the
rat P2X7 homolog (Jiang et al., 2000). The tetrazolylmethylpyridine derivative, A438079 (Nelson et al., 2006), and the adamantyl derivative, AZ10606120 (Michel et al.,
2008), are also potent, selective, and competitive P2X7 antagonists active at both the
human and rat P2X7 receptor. A biphenyl derivative, AZ11645373, also selectively
antagonizes the human P2X7 receptor, but is inactive at the rat P2X7 (North, 2002) and
other P2X subtypes (Stokes et al., 2006). Suramin, pyridoxal-phosphate-6-azophenyl2',4'-disulfonic acid (PPADS) and oxidised ATP have also been commonly used
antagonists of the human and rat P2X7 receptor, however their specificity has been
questioned (Di Virgillio, 2003). Thus, given the availability of KN-62, A-438079 and
the AZ11645373, the use of suramin, PPADS and oxidised ATP should be discouraged.
In addition to the above compounds, the P2X7 receptor is also impaired by
various extracellular ions. Virginio et al. (1997) carried out a comprehensive study of
the functional inhibition of P2X7 by divalent cations. They showed that Ca2+, Mg2+,
Zn2+ and Cu2+ all strongly inhibited both P2X7-mediated currents and YO-PRO-12+ dye
uptake. The divalent cations showed the same rank order of potency when inhibiting the
P2X7-mediated currents and dye uptake with Cu2+ > Cd2+ ~ Zn2+ > Ni2+ >> Mg2+ ~
Co2+ > Mn2+ > Ca2+ = Ba2+ >> Sr2+. Removal of Ca2+ and Mg2+ ions from media is
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thought to increase the availability of ATP4- required for P2X7 activation (North, 2002),
however, the inhibitory action of the other divalent cations remains unknown.
Extracellular Na2+ ions can also impair P2X7 receptor function. Michel et al. (1999)
have shown that the potency of BzATP for human P2X7 is approximately 20-fold
higher in sucrose medium (containing nominal amounts of Na2+) compared to NaCl
medium. Similarly, maximal response and efflux rates of P2X7 to ATP and BzATP are
higher in KCl medium compared to NaCl medium (Wiley et al., 1993; Stevenson et al.,
2009).
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Table-1.1 Human P2X subtypes.

P2X

Gene

amino

ATP EC50

subtypes

location

acids

(µM)

P2X1

17p13.3

399

1

P2X2

12q24.33

471

10

P2X3

11q12

397

1

P2X4

12q24.32

388

10

P2X5

17p13.3

422

10

ADP >> ATP

P2X6

22q11.21

431

6

ATP > αβmeATP

Rank agonist profile

αβmeATP ~ 2MeSATP >
ATP > ADP > BzATP
ADP ~ 2MeSATP > ATP >
BzATP >>> αβmeATP
αβmeATP ~ 2MeSATP >
ATP > ADP
2MeSATP >>> ATP >>
αβmeATP

BzATP > > ATP > >
P2X7

12q24

595

100

2MeSATP > ATPγS >>>
αβmeATP > ADP > UTP

Abbreviations: 2(3’)-O-(4-benzoylbenzoyl) adenosine 5’-triphosphate (BzATP),

2-

methylthio adenosine triphosphate (2MeSATP), adenosine 5’-diphosphate (ADP),
adenosine 5’-triphosphate (ATP), adenosine 5'-O-[3-thiotriphosphate] (ATP-γ-S), α-βmethyl ATP (αβmeATP), uridine 5’ triphosphate (UTP). Table adapted from North,
2002.
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1.2.8 Distribution of P2X7
P2X7 receptors have been identified on a variety of cell types by
electrophysiology techniques and other functional assays, reverse transcription
polymerase chain reaction (RT-PCR), immunocytochemistry, immunoblotting and gene
knock-out approaches. P2X7 receptors are highly expressed on cells from the
hematopoietic lineages, such as erythrocytes, T- and B-lymphocytes, eosinophils, mast
cells, monocytes, dendritic cells and macrophages (Sluyter et al., 2001, 2004, 2007; Gu
et al., 2000; Adinofi et al., 2002; Suh et al., 2001; Bulanova et al., 2005; Gudipaty et al.
2001; Wareham et al., 2009; Zhang et al., 2005). P2X7 receptors are also found
abundantly in brain glial cells (microglia, astrocytes, and Muller cells), bone cells
(osteoblasts, osteoclasts, and osteocytes), epithelial cells and endothelial cells (Gartland
et al., 2003; Bianco et al., 2005, 2006; Sugiyama et al., 2005; Li et al., 2005;
Pennolazzi et al., 2005; Li et al., 2003). P2X7 receptors have also been reported in
central and spinal cord neurons (Miras-Portugal et al., 2003; Leon et al., 2006; MarinGarcia et al., 2008), however the expression of P2X7 in these tissues remains
controversial (Sim et al., 2004). Expression of P2X7 receptors has also been found in
cells originating from the small intestine, kidney, urinary tract, uterus, and liver
(Hillman et al., 2005; Koshi et al., 2005; Emmett et al., 2008). P2X7 receptors have
also been observed in a variety of malignant cell lines (White and Burnstock, 2006)
including myeloid leukemic and epithelial cells, and are disclosed in greater detail in
Section 1.3, 1.4, 1.5.
1.2.9 P2X7 activation induces downstream signalling events
P2X7 receptor activation induces a number of downstream signalling events
including the release of pro-inflammatory cytokines and metalloproteases, reactive
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oxygen and nitrogen species formation, shedding of cell adhesion molecules, killing of
intracellular pathogens, and cell death and proliferation (Table 1.2). Of these the
maturation and release of interleukin (IL)-1β is the best described downstream
signalling event of P2X7 activation (Mariathasan and Monack, 2007; Ferrari et al., 2006)
and is discussed in further detail below. P2X7 activation can also induce cell death
(Adinolfi et al., 2005), but under some conditions and in certain cell types P2X7
activation may, conversely, induce cell proliferation (Di Virgilio, 2009). As a result of
this dual role of P2X7 in cell survival, this receptor is attracting interest for its growth
inhibitory and growth promoting roles in normal and malignant cell types (White and
Burnstock, 2006; Di Virgilio, 2009). Data supporting a role for P2X7 activation in cell
death and proliferation is discussed further below.
P2X7 activation induces IL-1β maturation and release
IL-1β is a pro-inflammatory cytokine predominantly released from monocytes,
macrophages and dendritic cells (Dinarello, 2005). Activation of P2X7 on these cells
leads to the maturation and release of this cytokine (Mariathasan and Monack, 2007;
Ferrari et al., 2006) (Fig. 1.2). IL-1β is constitutively present in macrophages, but is
normally absent in monocytes and dendritic cells. Stimulation of each of these cell types
with pathogen-associated molecular pattern molecules, such as lipopolysaccharide
(LPS), activate the nuclear factor-kappa beta (NF-κB) cascade to induce synthesis of
pro-IL-1β, but are unable to cause the functional maturation and release of this cytokine
(Dinarello, 2005; Ferrari et al., 2006; Mariathasan et al., 2006). A secondary stimulus,
such as ATP, is required for efficient processing and release of bioactive IL-1β
(Perregaux and Gabel, 1994, 1998). Activation of the P2X7 receptor by ATP leads to
the loss of cytoplasmic K+, and the assembly and activation of the NALP3 (NLRP3)
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inflammasome, a multi-protein complex that recruits pro-caspase-1 and induces its
proteolytic activation (Ferrari et al., 2006; Mariathasan et al., 2006). Pannexin-1 is also
critical for NALP3 inflammasome, and P2X7-mediated IL-1β maturation and release
(Pelegrin et al., 2008; Pelegrin and Surprenant, 2006, 2007). These studies
demonstrated that pannexin-1 is required for caspase-1 activation in response to ATP
suggesting a direct functional link between dye uptake, activation of caspase-1, and IL1β maturation and release. However the exact role of pannexin-1 in the IL-1β signalling
cascade including the NALP3 inflammasome remains to be fully determined
(Mariathasan and Monack, 2007). In addition to pannexin-1, P2X7-induced IL-1β
maturation and release is dependent on the activation of a Ca2+-independent
phospholipase A2 (iPLA2) following the decrease in cytoplasmic K+ concentration
(Andrei et al., 2004), however a link between the PLA2 and the NALP3 inflammasome
is yet to be determined.
The mechanism of IL-1β release is less clear. Studies have shown that the
activation of the P2X7 receptor induces shedding of microvesicles containing mature
IL-1β from the human monocytic cell line, THP-1 (MacKenzie et al., 2001) and
monocyte-derived dendritic cells (Pizzirani et al., 2007). However another study shows
that P2X7 activation causes the co-localisation of pro-IL-1β and caspase-1 in secretory
lysosomes in primary human monocytes, where it matures before secretion by
exocytosis (Andrei et al., 2004). Collectively, this data suggests that the maturation and
release of IL-1β varies according to cell type, state of differentiation or conditions used
for P2X7 receptor activation.
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Fig. 1.2 P2X7 activation induces IL-1β maturation and release. Activation of P2X7 by
ATP results in K+ efflux and the activation of pannexin-1 to activate the NALP3
(nucleotide-binding domain and leucine-rich repeat containing a pyrin domain) complex
containing the adaptor molecule ASC (apoptosis-associated speck-like protein
containing a CARD) and cardinal. This complex aggregates pro-caspase-1 molecules to
form an inflammasome complex that facilitates pro-caspase-1 activation and subsequent
pro-IL-1β processing to its mature IL-1β form. Loss of cytoplasmic K+ by P2X7 also
activates a calcium-independent phosholipase A2 (iPLA2) to activate pro-caspase-1 and
the processing of pro-IL-1β to its mature form. Figure adapted from Pelegrin and
Surprenant (2009)
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P2X7 activation induces cell death
It has been known for close to three decades that extracellular ATP can induce
cell death by either apoptosis or necrosis (Di Virgillio et al., 1998). However despite
many reports of ATP-induced cell death, and that this effect is often induced by P2X7
activation (Adinolfi et al., 2005), the mechanisms involved in P2X7-induced apoptosis
or necrosis remain poorly defined. This is attributed in part to the limited use of
experimental parameters to clearly define cells as having undergone apoptosis or
necrosis (Kroemer et al., 1998). Moreover, the downstream pathways involved in
P2X7-induced cell death appear to differ between various cell types and experimental
conditions making comparisons between individual studies difficult. In 1999, Ferrari
and colleagues provided some of the earliest evidence that P2X7 induces apoptosis. In
this study, high concentrations of ATP (3 mM) induced condensation of nuclei, DNA
fragmentation and caspase-1, -3 and -8 activation in mouse microglial N3 and N8 cells
(Ferrari et al., 1999). Similarly, high concentrations of ATP (5 mM) induced apoptosis
in mouse BAC1 macrophages, as evidenced by DNA fragmentation and caspase-3
activation (Humphreys et al., 2000). Moreover, this process was impaired by KN-62
directly implicating P2X7 in this ATP-induced apoptosis. Similar evidence for P2X7
activation in ATP-induced apoptosis has also been observed in mouse RAW264.7
macrophages (Noguchi et al., 2008). Recently, Di Virgilio (2009) proposed a
mechanism by which P2X7 activation induces apoptosis (Fig. 1.3). In this model,
sustained P2X7 activation by high concentrations of ATP causes a collapse of the
mitochondrial membrane potential to activate the caspase pathway to induce apoptosis.
Further roles for P2X7 in ATP-induced cell death in other cell types such as epithelial
cells, as well as myeloid and lymphoid leukemic cells is discussed further below.
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P2X7 activation induces cell proliferation
Activation of the P2X7 receptor can induce the proliferation of certain cell types
including P2X7-transfected leukemic, K562 and LG14 cell lines, and normal and
leukemic T- and B-lymphocytes (Adinolfi et al., 2002; Baricordi et al., 1996, 1999;
Budagion et al., 2003; Yip et al., 2009). The molecular basis underlying this process is
not well understood. In an attempt to understand the mechanism involved in P2X7mediated cell proliferation, Adinolfi et al (2005) showed that HEK-293 cells transfected
with the P2X7 receptor resulted in higher resting concentrations of mitochondrial Ca2+
and the subsequent release of large amounts of Ca2+ from intracellular stores. In turn,
this Ca2+ increase stimulated NADH synthesis and ATP production via oxidative
phosphorylation. This increased intracellular ATP content facilitated cell survival and
growth. In a recent study by the same group, P2X7 expression in transfected HEK-293
cells increased intracellular Ca2+ by disrupting endoplasmic reticulum function to
activate the nuclear factor of activated T-cells (NFATc1) to enhance cell survival and
protect the cells from apoptosis (Adinolfi et al., 2009). This mechanism of P2X7induced cell proliferation is shown in Fig. 1.3 Other mechanisms of P2X7-induced
proliferation have also been described in chronic lymphocytic leukemia (CLL) Blymphocytes, and normal and malignant T-lymphocytes and are discussed further below.
Despite the varying mechanisms involved in P2X7-induced cell death and proliferation,
one common feature of P2X7-induced cell proliferation is that, this process is
stimulated by low amounts or basal amounts of ATP added to or released from the cells
respectively (Di Virgilio, 2009), in contrast to P2X7 induced cell death, which requires
at least 10-fold higher concentrations of ATP (Adinolfi et al., 2005).
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Fig.1.3 Schematic representation of P2X7 as a growth-promoting and death-inducing
receptor. Basal activation of the P2X7 receptor leads to a moderate increase in
cytoplasmic Ca2+, which causes an elevation of intramitochondrial Ca2+ that stimulates
NADH synthesis and ATP production via oxidative phosphorylation. Increased cellular
ATP content then facilitates cell survival and growth. Prolonged activation of the P2X7
receptor causes uncontrolled influx of Ca2+, which triggers loss of mitochondrial
membrane potential followed by activation of caspase 9/7/3-mediated cell death. Figure
adapted from Di Virgilio et al (2009).
P2X7 activation induces reactive oxygen species production
Several studies have indicated a role for P2X7-mediated reactive oxygen species
(ROS) production. Lenertz et al (2009) showed that P2X7 mediates ROS production in
primary human monocytes and RAW264.7 macrophages, and that generation of ROS
most likely involves activation of ERK1/2 and the NADPH oxidase complex. These
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findings were consistent with that of Noguchi et al. (2008) who demonstrated that
P2X7-induced ROS production in RAW264.7 macrophages is sensitive to the NADPH
oxidase inhibitor apocynin and can be prevented by reducing the expression of the
NADPH subunit gp91phox in these cells. Moreover, this study demonstrated that ROS
formation plays a role in P2X7-induced apoptosis of RAW264.7 macrophages; however,
a role for ROS in P2X7-induced apoptosis has not been reported by others.
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Table 1.2: Signalling mechanisms and cellular functions of the P2X7 receptor
Cell type(s)

Reference(s)

Signalling

Cellular

mechanism(s)

function(s)

Dendritic cells,

K+ efflux, NALP3

IL-1β and IL-18

Perregaux and Gabel,

macrophages,

inflammasome,

maturation and

1994; Andrei et al.,

microglia,

caspase-1, PLA2,

release

2004; Hewinson, et al.,

monocytes,

RONS, pannexin-

2008; Mariathasan et

1

al., 2006; Pelegrin and
Surprenant, 2006

T- and B-

Ca2+ influx,

lymphocytes,

NFAT, p38,

Baricordi et al., 1999;

microglia,

pannexin-1

Ferrari et al., 1999;

Cell proliferation Adinolfi et al., 2006;

erythroleukamic

Loomis et al., 2003;

cells

Yip et al., 2009
Cell death

Ferrari et al., 1999;

B-lymphocytes,

JNK, p38,

macrophages,

NADPH oxidase,

Humphreys et al., 2000;

microglia

caspase-3 and -8

Noguchi et al., 2008;

Macrophages

JNK, p38,

ROS formation

Lenertz et al, 2009;
Noguchi et al., 2008;

NADPH oxidase

Pfeiffer, et al., 2007
B-lymphocytes,
dendritic cells

ADAM-10

CD23 shedding

Gu et al., 1998; Le Gall
et al., 2009; Sluyter and
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Wiley, 2002
B- and T-

ADAM-17

CD62L shedding

Gu et al., 1998; Le Gall

lymphocytes,

et al., 2009; Sluyter et

monocytes

al., 2004; Seman et al.,
2003
Ca2+ influx

MMP-9 release

Gu and Wiley, 2006

P2X7-transfected

p38, Rho, PLD,

Actin

Morelli et al., 2003;

fibroblasts,

PLA2, LPA

reorganization

Pfeiffer, et al., 2004;

macrophages,

and membrane

Verhoef et al., 2003

osteoblasts

blebbing

B- and Tlymphocytes,
monocytes

Endothelial cells,

Ca2+ influx

erythroleukamic

Microvesicle

Baroni et al., 2007;

release

Bianco et al., 2005;

cells, dendritic cells,

Constantinescu et al.,

macrophages,

2010; Wilson et al.,

microglia,

2005

Dendritic cells

Exosome release

Qu et al., 2009

Ca2+ influx, PLD,

Killing of

Kusner and Adams,

phagolysosome

intracellular

2001; Stober et al.,

NALP3
inflammasome

Macrophages

mycobacteria
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fusion

and chlamydia

2001

Abbreviations: IL, interleukin; JNK, Jun N-terminal Kinase; LPA, lysophosphatidic
acid; PLA2, phospholipase A2; PLD, phospholipase D; RONS, reactive oxygen and
nitrogen reactive species; ROS, reactive oxygen species
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1.3 Role of P2X7 in THP-1 Monocytes
Following on from the pioneering work of Blanchard (Spranzi et al., 1993) and
Dubyak (Humphreys and Dubyak, 1996, 1998; Humphreys et al, 1998) and their
colleagues, the human leukemic monocytic cell line THP-1 has become a wellestablished model to study the expression and function of P2X7. THP-1 cells express no
to low amounts of P2X7, however the expression of this receptor can be induced
following differentiation with IFN-γ and LPS, or to a lesser extent with 12-myristate 13acetate (PMA) (Humphreys and Dubyak, 1998). Similarly, P2X7 expression and
function is upregulated upon differentiation of monocytes to macrophages (Hickman et
al., 1994). Moreover, pro-inflammatory molecules such as interferon-γ (IFN)-γ, tumour
necrosis factor-α and lipopolysaccharide (LPS) can up-regulate P2X7 expression and
function in monocytes/macrophages (Blanchard et al, 1991; Buell et al., 1998; Gudipaty
et al., 2001). Thus, due to the effects of P2X7 in monocytes and macrophages, the THP1 cell line is considered as a suitable model to study P2X7 in monocytes/macrophage
biology. Moreover, THP-1 cells differentiated with IFN-γ and LPS demonstrate
characteristics of primary macrophages including plastic adherence (Humphreys and
Dubyak, 1998), phagocytosis of latex beads (Gu et al., 2010) and killing of intracellular
mycobacteria (Kusner et al., 2000)
Activation of P2X7 in differentiated THP-1 cells results in number of
downstream signalling events including: cation fluxes (Humphreys and Dubyak, 1998);
cell lysis (Spranzi et al., 1993); activation of phospholipase D (Humphreys and Dubyak,
1996), mitogen-activated protein kinases (Aga et al., 2002) and caspase-1 (Verhoef et
al., 2005); nuclear translocation of NF-κB (Aga et al., 2002); dissociation of nonmuscle
myosin from the P2X7 complex (Gu et al., 2009) and subsequent inhibition of
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phagocytosis (Gu et al., 2010); release of mature IL-1β (Grahames et al., 1999) and IL18 (Bachmann et al., 2006); shedding of microvesicles (MacKenzie et al., 2001); and
killing of intracellular mycobacteria (Kusner et al., 2000). THP-1 monocytes have also
been widely used to screen a number of potential P2X7 antagonists leading to the
development of some highly specific and potent P2X7 antagonists (Nelson et al., 2006;
Stokes et al., 2006). Finally, this cell line was used to establish the blocking action of
the only available human anti-P2X7 monoclonal antibody (mAb) (Buell et al., 1998).
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1.4 Role of P2X7 in Epithelial Cancer
The P2X7 receptor is thought to play an important physiological role in the
physiology and pathophysiology of normal and malignant epithelial cells (Gorodeski,
2009). Moreover, ATP is present in the extracellular milieu of epithelial tissues at
concentrations sufficient to activate the P2X7 receptor (Gorodeski, 2009). Most data
supporting a role for P2X7 in epithelial tissues is based on studies with colon, skin and
cervical epithelial cells.
A number of studies have examined the expression and function of the P2X7
receptor in normal and malignant epithelial colon cells, although direct evidence for this
receptor in these cells is limited. Selzner et al (2004) observed that extracellular ATP
induced apoptosis of the human epithelial colon cancer cell lines, SW403, HCT 116 and
Colo. Moreover, this ATP-induced apoptosis was mediated by the release of
cytochrome c and subsequent activation of caspase 3. Finally, the authors attributed this
effect to P2X7 receptor activation, as the various cell lines expressed this receptor,
however direct pharmacological evidence was lacking. Following on from the
observations, Coutinho-Silva et al (2005) demonstrated the presence of low levels of
P2X7 mRNA and P2X7-induced Ca2+ fluxes in the human epithelial colon carcinoma
cell lines, HCT-8 and Caco-2. A dual role for P2 receptor signalling was implicated in
these cell lines, as ATP induced cell proliferation at low concentrations, but at higher
concentrations induced apoptosis. Moreover, oxidised ATP partially blocked this ATPinduced apoptosis which lead the authors to conclude that this process was mediated by
P2X7, however direct pharmacological evidence using more specific P2X7 antagonists
was lacking. Subsequently, the authors demonstrated that IFN-γ increased the
susceptibility of HCT-8 cells to ATP-induced apoptosis, however the effect of IFN-γ on
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P2X7 mRNA or protein was not examined (Welter-Stahl et al., 2009). Moreover, direct
pharmacological evidence for P2X7 in mediating ATP–induced apoptosis was again
lacking. Finally, Li et al (2009) have shown that the level of P2X7 expression is similar
in normal and cancer colon cells, which is in contrast to other epithelial cell types,
including those from the cervix and skin, where P2X7 is approximately 2-fold lower in
the malignant cells compared to normal cells. The significance of these latter findings is
not well understood.
A number of groups have detected the presence of functional P2X7 receptors in
normal and malignant skin epithelial cells (Holzer and Granstein, 2004; White and
Burnstock, 2006). A role for skin epidermal P2X7 in inflammatory and immune
processes has been suggested (Georgiou et al., 2005), but direct evidence was lacking at
the time. Subsequently, others have shown that P2X7 activation can impair the release
of the chemokine CXCL16 from cultured human normal keratinocytes (Pastore et al.,
2007), while others have reported that treatment of these cells with BzATP induces IL-6
release (Inoue et al., 2007). More, recently Fu et al. (2009) have shown that P2X7
activation induces apoptosis of cultured normal mouse keratinocytes. Furthermore, this
process was dependent on a Ca2+ influx and the subsequent activation of caspase-9 (or
mitochondrial) apoptotic pathway. Of note, this paper went on to demonstrate that P2X7
activation could prevent the formation of skin papillomas and cancer in mice following
treatment with chemical carcinogens supporting a role for P2X7 activation in vivo.
A series of studies from the laboratory of Gorodeski provide evidence for a role
for P2X7 in normal and malignant cervical epithelial cells. BzATP induces cell death in
both normal human ectocervical epithelial cells and the human epithelial ecto-cervical
CaSki cell line in a Ca2+- and caspase-9-dependent manner, suggesting that P2X7
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activation induces the apoptotic mitochondrial pathway in these cells (Wang et al.,
2004). A direct role for P2X7 in this process was established when it was shown that
co-expression of the P2X7-j variant (Section 1.1.2) with full-length P2X7 blocked
BzATP-induced apoptosis in these cells (Feng et al., 2006). Other studies demonstrated
that both estrogen and epinephrine can impair the P2X7-induced apoptosis of human
cervical epithelial cells (Gorodeski, 2004; Wang et al., 2005). Estrogen impaired P2X7induced apoptosis by decreasing Ca2 + influx and the subsequent increase in cytosolic
Ca2 + increase via ATP-activated P2X7 pores (Gorodeski, 2004). These results suggest
that estrogen may have an anti-apoptotic role within the cervix. The inhibitory effect of
epinephrine was due to increased degradation of full-length P2X7 and the subsequent
decrease of total P2X7 protein resulting in reduced P2X7-induced pore formation and
apoptosis. Finally, Li et al (2009) showed that the amounts of full-length P2X7 are
lower in cervical and uterine epithelial cancer tissues than in corresponding normal
tissues. Thus, tissue analysis of P2X7 mRNA and protein levels could be used as a
novel biomarker to differentiate between normal and malignant cells in these epithelial
tissues.
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1.5 Role of P2X7 in Leukemia
Functional P2X7 receptors have been reported in various myeloid and lymphoid
leukemias, as well as multiple myeloma. P2X7 has been identified in a number of
myeloid leukemic cell lines, however evidence of this receptor in primary myeloid
leukemias is lacking. In addition to THP-1 cells (Section 1.3), P2X7 mRNA has been
observed in the human myeloid leukemic HL-60 and F-36P cell lines (Yoon et al.,
2006). Moreover, ATP induced cell cycle arrest in these cell lines, but the identity of the
P2 receptor was not established (Yoon et al., 2006). P2X7 mRNA and protein has also
been observed in the human myeloid leukemic KG1a cell line, but lacked functional
ATP-induced responses in NaCl medium (Zhang et al., 2004). However, subsequent
studies of this cell line in sucrose medium have revealed that BzATP can induce Ca2+
fluxes, pore formation and cell death in this cell line (Zhang et al., 2009). Moreover,
this latter study showed that oxidised ATP could impair these BzATP-induced
responses, but other direct evidence for involvement of the P2X7 receptor was lacking.
Finally, there are no reports as to whether the parental myeloid leukemic cell line, KG-1
(from which KG1a cells are derived) expresses functional P2X7.
P2X7 is present in malignant B-lymphocytes from patients with chronic
lymphocyte leukaemia (CLL) (Gu et al., 2000; Wiley and Dubyak, 1989;). Activation
of P2X7 in this cell type results in cell death (Adinolfi et al., 2002; Wiley et al., 2002).
Conversely, a role for P2X7 in the proliferation of CLL B-lymphocytes has also been
proposed since CLL B-lymphocytes from patients with more progressive forms of the
disease have higher rates of cell proliferation, and correspondingly increased amounts of
functional P2X7, compared to cells from patients with indolent forms of CLL (Adinolfi
et al., 2002). This dual role of P2X7 in cell death and proliferation most likely reflects
42

differences in ATP concentrations (high versus low respectively) as discussed by Di
Virgilio and Wiley (2002). P2X7 activation can also induce the rapid shedding of cellsurface CD23 (the low affinity IgE receptor) from CLL B-lymphocytes via stimulation
of a membrane metalloprotease (Gu et al., 1998). Although the identity of this
metalloprotease was not established, more recent data indicate a role for ADAM10 in
the P2X7-induced shedding of CD23 from P2X7-transfected Chinese hamster ovary
cells and murine B-lymphocytes (Le Gall et al., 2009). Whether P2X7 is present in
other types of human B-lymphocyte malignancies, apart from CLL, is unknown.
However Farrell (2008) showed that the human multiple myeloma RPMI 8226 cell line
expresses functional P2X7, and that activation of this receptor induces cell death and the
rapid shedding of CD23 from the surface of these cells. Thus, this cell line provides a
useful model to study the role of human P2X7 in multiple myeloma and as a positive
control for other P2X7 studies.
The physiological and pathophysiological role of P2X7 in normal and malignant
B-lymphocytes is not fully understood. So far there have been no reports of defects in
B-lymphocyte mediated responses in P2X7 knockout mice (Chessell et al., 2005; Solle
et al., 2001). Moreover, defects in B-lymphocyte function have not been attributed to
altered disease outcomes in models of inflammatory or immune-mediated disorders in
these mice (Chen et al., 2006). Both enhanced P2X7-induced cell proliferation, due to
high P2X7 amounts (Adinolfi et al., 2002), and defects in P2X7-induced cell death, due
to the E496A loss-of-function polymorphism (Wiley et al., 2002; Thunberg et al., 2002)
have been postulated to alter disease outcomes in CLL (Virgilio and Wiley, 2002),
however neither hypothesis has been substantiated by additional data (Sellick et al.,
2004). Moreover, the E496A polymorphism is not associated with disease outcomes in
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multiple myeloma (Paneesha et al., 2006). However, it should be noted that this loss-offunction polymorphism reduces P2X7 function by approximately 50% in heterozygous
dosage (Gu et al., 2001), but does not inhibit P2X7 channel function (Boldt et al., 2003)
nor completely impairs P2X7 function in homozygous dosage (Sluyter et al., 2004).
Thus, the possibility remains that P2X7 may still play a role in B-lymphocyte
malignancies independently of this polymorphic variation.
P2X7 is also present in human leukemic Jurkat T cells. Yip et al (2009) have
recently shown that T-cell receptor (TCR) activation in Jurkat T cells, as well as
primary human CD4 + T-lymphocytes up-regulates P2X7 mRNA and triggers the release
of ATP which feeds back on these cells to further induce TCR-mediated Ca2+ influx,
NFAT activation and interleukin-2 production to drive cell proliferation. Moreover,
they have shown that T-lymphocyte activation is impaired in C57BL/6 mice that
express low levels of functional P2X7, compared to BALB/c mice, which express fully
functional P2X7 receptors. Prior to these observations, Budagion et al (2003) showed
that treatment of Jurkat T cells with millimolar concentrations of extracellular ATP
resulted in the phosphorylation and activation of p56 lck kinase, extracellular signalregulated kinase (ERK), and c-Jun N-terminal kinase and the subsequent production of
IL-2 and cell proliferation. These effects were shown to be completely dependent upon
the presence of extracellular Ca2+ ions in the culture medium and pharmacological data
supported the role of P2X7 in these ATP-induced effects in Jurkat T cells. Finally, the
P2X7 mRNA has also been reported in primary lymphoid malignancies (Zhang et al.,
2004), however the authors failed to report if they originated from either B- or Tlymphoid cells.
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1.6 Transforming growth factor-β1
Transforming growth factor-β1 (TGF-β1) is a pleiotropic cytokine involved in a
variety of biological processes including inflammation and immunity, where it is
involved in homeostasis and tolerance, as well as the initiation and resolution of the
immune response (Li et al., 2006). TGF-β1 belongs to the TGF-β superfamily, which
includes three isoforms of TGF-β (TGF-β1 to -β3) (Li et al., 2006). TGF-β is
synthesized as a pre-pro-TGF-β precursor molecule which requires subsequent
processing by a furin-like peptidase within the Golgi apparatus (Li et al., 2006). The
process product is then released from the cell in a latent form, but requires additional
processing by changes in pH or heat or by several proteases before it can bind to its
respective receptor (Li et al., 2006). Active forms of TGF-β bind to the Type II TGF-β
receptor. This receptor then recruits, phosphorylates and activates the Type I TGF-β
receptor. The TGF-β receptor also forms a complex with activin receptor-like kinase 5
(ALK5) to help mediate cell signalling.
A number of mechanisms of TGF-β signalling have been proposed including
Smad-dependent and -indpendent signalling (Li et al., 2006). Smad-dependent
signalling occurs as a result of signalling via phosphorylated ALK5 and the Type I
TGF-β receptor following TGF-β binding. These phosphorylated molecules in turn,
phosphorylate receptor-activated Smads (R-Smads: Smad1, Smad2, Smad3, Smad5, and
Smad8). Once phosphorylated, R-Smads associate with the co-mediator Smad, Smad4,
and the heteromeric Smad complex then translocates to the nucleus. In the nucleus,
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Smad complexes activate specific genes through cooperative interactions with other
DNA-binding and co-activator (or co-repressor) proteins (Shi and Massague, 2003).
TGF-β1 is the predominant TGF-β isoform expressed in the immune system.
TGF-β1 has been associated with both pro- and anti-inflammatory functions on
monocytes/macrophages through multiple mechanisms. For instance, TGF-β1 can
induce IL-1, IL-6 and matrix metalloproteinases (MMPs) release from monocytes, and
can facilitate monocyte migration to sites of infection and inflammation (Han et al.,
2000; Wahl et al., 1993). Conversely, TGF-β1 can down-regulate CD14 or MHC class
II expression in IFN-γ- or LPS-treated macrophages respectively (Nandon et al., 1997).
TGF-β1 can also down-modulate the expression and function of several other cellsurface receptors in other cell types including CD1d on dendritic cells (Ronger-Savle et
al., 2005), FcεRI on mast cells (Gomez et al. 2005) and Fas on follicular dendritic cells
(Park et al., 2005). Finally, data from our laboratory has shown that TGF-β1 can downregulate P2X7 cell-surface expression and P2X7 function (ATP-induced ethidium+
uptake) in IFN-γ and or LPS-treated THP-1 monocytes (Tran, 2007; Georgiou and
Sluyter, personal communication), however the mechanism of action of TGF-β1 in this
process was not established. While other, data from our laboratory, has shown that
monocyte-derived dendritic cells generated in the presence of TGF-β1 have decreased
amounts of P2X7 function (ATP-induced ethidium+ uptake) compared to monocytederived dendritic cells generated in the absence of TGF-β1 (Georgiou et al., 2005).
However, in contrast to THP-1 cells, this difference in dendritic cells correlated with
differences in cell-surface CD39 (ecto-ATPDase) but not P2X7 expression (Georgiou et
al., 2005). Whether TGF-β1 effects P2X7 in other cell types is unknown.
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1.7 AIMS
This thesis aims to examine the expression and function of the P2X7 receptor in
human malignant myeloid and epithelial cell lines. Specifically, the aims are to:
(1) Determine the mechanism by which TGF-β1 prevents the up-regulation of P2X7
expression and function in IFNγ and LPS-treated myeloid leukemic THP-1 cells;
(2) Confirm if the colon epithelial HCT-8 and Caco-2 cell lines express functional
P2X7 receptors, and whether activation of this receptor induces cell death;
(3) Determine if the myeloid leukemic KG-1 cell lines expresses functional P2X7
receptors.
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Chapter 2: Materials and Methods
2.1 Materials
RPMI-1640 medium (containing 10 mM HEPES), foetal calf serum (FCS;
inactivated before use), 0.25% trypsin solution, Dulbecco’s phosphate-buffered saline
(PBS), L-glutamine, Superscript III One-Step RT-PCR System Platinum Taq DNA
polymerase and penicillin-streptomycin were from Invitrogen Corporation (Auckland,
New Zealand). Adenosine 5'-triphosphate (ATP), adenosine 5'-diphosphate (ADP),
2(3’)-O-(4-benzoylbenzoyl) adenosine 5'-triphosphate (BzATP), uridine 5'-triphosphate
(UTP), ethidium bromide, lipopolysaccharide (LPS; Escherichia coli 055:B5), nonessential amino acids, 6-aminohexanoic acid, propidium iodide, trypan blue solution
and 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) were from
Sigma-Aldrich (St. Louis, Missouri, U.S.A.). Stocks of ATP (100 mM) were prepared
in double distilled water, the pH adjusted to 7.5 with 1 mM NaOH, and stored in
aliquots at -80oC. YO-PRO-1 was from Molecular Probes (Invitrogen, Eugene, OR,
U.S.A.).

Dimethyl

sulphoxide

(DMSO),

n-dodecyl

β-D-maltoside,

phenylmethylsulfonyl fluoride (PMSF), 2-mercaptoethanol, Tween-20, Triton X-100,
sodium dodecyl sulphate (SDS) and other general reagent grade chemicals were
obtained from Amresco (Solon, Ohio, U.S.A.). 5,7-dibromo-N-(p-hydroxymethyl
benzyl) isatin (isatin) was kindly provided by Dr Kara Perrow (University of
Wollongong, Wollongong, Australia). 1-(N, 0-bis(5-isoquinolinesulphonyl)-N-methylL-tyrosyl)-4-phenylpiperazine (KN-62), phorbol 12-myrisate 13-acetate (PMA),
adenosine-5'-O-(3-thio) triphosphate (ATP-γ-S) and 7-amino-actinomycin-D (7AAD)
were from Alexis Biochemicals (Lausen, Switzerland). A-438079 and AZ10606120
were from Tocris Bioscience (Park Ellisville, Missouri, U.S.A.). Human AB+ serum
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was from the Australian Red Cross Blood Service (Penrith, Australia). Precision Plus
Protein Standards (Dual colour), nitrocellulose membrane and Precison Protein
StrepTactin-HRP conjugate were from Bio-Rad (Hercules, California, U.S.A.) and 420% gradient iGels were obtained from NuSep (Austell, Georgia, U.S.A.). MiniComplete protease inhibitor cocktail tablets and interferon-gamma (IFN-γ) were from
Roche Applied Science (Mannheim, Germany). Transforming growth factor (TGF)-β1
was from R&D Systems (Minneapolis, Minnesota, U.S.A.). SuperSignal® West Pico
Chemiluminescent Substrate was from Pierce (Rockford, Illinois, U.S.A.). BD Falcon
70 µm cell strainers were from Becton Dickinson Labware (Franklin Lakes, New Jersey,
U.S.A.) and used to filter adherent cell lines before flow cytometric analysis.
Murine anti-human P2X7 (clone L4) monoclonal antibody (mAb) (Buell et al.,
1998) was purified and conjugated to fluorescein isothiocyanate (FITC) or Alexa Fluor
647 by Dr Ben Gu (University of Sydney, Penrith, Australia) or Dr Ronald Sluyter
(University of Wollongong) respectively. Murine FITC- and Alexa 647-conjugated
P2X7 isotype control mAb were from eBioscience (San Diego, California, U.S.A.).
Rabbit anti-rat P2X7 polyclonal antibody (Ab) (C-terminal epitope) was from Alomone
Labs (Jerusalem, Israel). Rabbit anti-actin Ab was from Sigma-Aldrich. FITCconjugated murine anti-human CD14 (clone TUK4) and isotype control mAb were from
Dako (Glostrup, Denmark). FITC-conjugated murine anti-human CD86 (clone 2331)
and MHC class II (HLA-DR; clone L243) mAb were from BD Biosciences (San Jose,
California, U.S.A.). HRP-conjugated goat anti-rabbit IgG Ab was from Rockland
(Gillbertsville, Pennsylvania, U.S.A.).
2.2 Cell lines
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The human leukemic monocytic cell line THP-1 was from the American Type
Culture Collection (Rockville, Maryland, U.S.A.). The human myeloma cell line RPMI
8226, the epithelial colon cancer cell lines HCT-8 and Caco-2, and the acute
myelogenous leukemic cell line KG-1 were obtained from the European Collection of
Cell Cultures (Porton Down, UK). RPMI 8226, THP-1 and HCT-8 cells were
maintained in RPMI-1640 medium supplemented with 10% FCS and 5 mM Lglutamine. Caco-2 and KG-1 cells were maintained in RPMI-1640 medium
supplemented with 20% FCS, 5 mM L-glutamine and 100 µg/mL penicillinstreptomycin, according to the cell supplier’s recommendations. Cells were incubated at
37ºC/5% CO2 and passaged every 3-4 days as required. The adherent cell lines, HCT-8
and Caco-2, were harvested using 0.25% trypsin solution.
THP-1 cells were differentiated as described (Humphreys and Dubyak, 1998).
Briefly, cells were plated at 1 × 106 cells/mL and cultured for 3 days in 5 ml fresh
complete media containing 1000 U/mL IFN-γ and 1 μg/mL LPS, with or without
5ng/mL TGF-β1. Untreated THP-1 cells were plated at 3 × 105 cells/mL and cultured as
above.
In some experiments HCT-8 cells were incubated with IFN-γ as described
(Welter-Stahl et al., 2009). HCT-8 cells were plated at 1 × 106 cells/mL and cultured for
3 days in 5 mL fresh complete media in the presence and absence of IFN-γ (0, 1, 10,
100 or 1000 U/mL).
2.3 Expression of P2X7 and other cell surface markers by immunofluorescence
staining
Cells were washed twice with NaCl medium (145 mM NaCl, 5 mM KCl, 5 mM
D-glucose, 0.1% BSA, 10 mM HEPES, pH 7.5). Cells (5 × 105) were then incubated
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for 20 min at room temperature with either specific or corresponding isotype control
mAb in 100 µL NaCl medium containing 10% human AB+ serum, 0.01% NaN3 and 0.1
µg/mL 7AAD. The cells were washed once in 2 mL NaCl medium, centrifuged at 300 g
for 5 min and the data was acquired using a LSR II flow cytometer and FACSDiva
software (BD Biosciences). The mean fluorescence intensity (MFI) was determined
using FlowJo software (Tree Star, Ashland, Oregon, U.S.A.).
2.4 P2X7 expression by immunoblotting
Whole cell lysates were prepared as described (Gu et al., 2004). Cells were
washed three times at 300 g for 5 min in ice-cold PBS and then lysed (1 × 10 7 cells/mL)
in lysis buffer (50 mM Bis-Tris, 750 mM 6-aminohexanoic acid, 1 mM
phenylmethylsulphonyl fluoride, 1% n-dodecyl β-D-maltoside and Mini-Complete
protease inhibitors, pH 7.0) over 60 min, sheared ten times through a 21 gauge needle
and centrifuged at 16,000 g for 10 min at 4ºC. Cell supernatants were then separated
under reducing conditions (5% 2 β-mercaptoethanol) using 4-20% gradient iGels (50V
for 120 min at 4ºC) and transferred to nitrocellulose membranes (Bio-Rad) (80V for 90
min at 4ºC). Nitrocellulose membranes were blocked overnight at 4ºC with Trisbuffered saline (250 mM NaCl, 50 mM Tris, pH 7.5) containing 0.2% Tween-20 and
5% skim milk powder, and then incubated for 2 h at room temperature with anti-P2X7
Ab diluted in Tris-buffered saline containing 0.2% Tween-20 and 5% skim milk powder.
Membranes were washed three times over 30 min with Tris-buffered saline containing
0.2% Tween-20 and then incubated for 1 h at room temperature with HRP-conjugated
anti-rabbit IgG Ab and Precision Protein StrepTactin-HRP conjugate and diluted in
Tris-buffered saline containing 0.2% Tween-20 and 5% skim milk powder. Membranes
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were washed as above, incubated with chemiluminescent substrate and visualised using
Amersham Hyperfilm ECL (GE Healthcare, Little Chalfont, Buckinghamshire, UK).
2.5 P2X7 expression by RT-PCR
Cells were washed once in sterile PBS medium. Total RNA was isolated from
cells using an RNeasy Mini Kit (Qiagen, Hilden, Germany) according to the
manufacturer’s instructions. Total RNA was converted to cDNA using Superscript III
One-Step RT-PCR System Platinum Taq DNA polymerase at 55ºC for 30 min
according to the manufacturer’s instructions. Previously described primers to P2X7
(forward

primer

5’-GGATGGTGAACCAGCAGCTA-3’;

reverse

primer

5’-

AAGCCACTGTACTGCCCTTC-3’) (Skarratt et al., 2005) and β-actin (forward 5′TGGTGGGCATGGGTCAGAAG-3′; reverse 5′-GTCCCGGCCAGCCAGGTCCAG-3′)
(Wareham et al., 2009) were obtained from Sigma-Genosys (Castle Hill, Australia).
PCR amplification was performed using 30 cycles (95ºC, 15 s; 50ºC, 30 s; 72ºC, 60 s)
for P2X7 and 30 cycles (95ºC, 15 s; 61ºC, 30 s; 72ºC, 60 s) for β-actin. PCR products
were separated on a 2% agarose gel and visualised using ethidium bromide staining.
2.6 Measurement of dye uptake by flow cytometry
P2X7 agonist-induced dye uptake into cells was measured using a fixed-time
assay (Georgiou et al., 2005). Cells (5 × 10 5) resuspended in 1 mL NaCl medium
(Section 2.3), KCl medium (150 mM KCl, 10 mM D-glucose, 0.1% BSA, 10 mM
HEPES, pH 7.5) or sucrose medium (280 mM Sucrose, 5 mM KCl, 0.5 mM CaCl2, 10
mM NMDG, 20 mM HEPES, 5 mM D-glucose, 0.1% BSA pH 7.4) or sucrose medium
without Ca2+ were incubated with 25 µM ethidium+ or 1 µM YO-PRO-1(Invitrogen,
Eugene, OR, U.S.A.) in the absence or presence of nucleotide at 37 oC, as indicated. In
some experiments, cells were pre-incubated with 1 μM KN-62, 0.1 μM AZ10606120 or
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DMSO (diluent control), or in the presence or absence of 10 μM A-438079 or H2O
(diluent control) for 15 min at 37oC before the addition of a nucleotide. Incubations
were stopped by the addition of an equal volume of ice-cold MgCl2 medium (20 mM
MgCl2, 145 mM NaCl, 5 mM KCl and 10 mM HEPES, pH 7.5) and centrifugation at
300 g for 5 min. Cells were then washed with 2 mL NaCl medium and analysed by flow
cytometry. The MFI of dye uptake was determined using the FlowJo software.

2.7 IL-1β release measurements
ATP- and nigericin-induced IL-1β release from THP-1 cells was measured using
a modification of a protocol used previously for human monocytes (Sluyter et al., 2004).
THP-1 cells were suspended at 5 × 105 viable (trypan blue exclusion) cells/mL in
RPMI-1640 medium containing 0.1% BSA (pH 7.5) and plated into 24-well plates (0.5
mL/well). Cells were incubated in the absence or presence of 3 mM ATP or 20 μM
nigericin for 15 min at 37 °C/5% CO2. The samples were then centrifuged at 11,000 g
for 10 s and the cell-free supernatants stored at -20°C for less than two weeks before
assaying. Amounts of IL-1β were measured using a human IL-1β ELISA (eBioscience)
according to the manufacturer's instructions.
2.8 Measurement of cell number by a colorimetric tetrazolium-based assay
Quantification of cell numbers following sustained application of P2X7 agonists
was studied using the MTT colorimetric assay as described by Coutinho-Silva et al
(2005). Cells in their respective culture medium (3 × 10 3 cells/100 μL/well) were seeded
in triplicate into 96 well plates and incubated for 24 hours at 37 oC/5% CO2. Cells were
then incubated in the absence or presence of nucleotide or isatin for a further 24 or 48 h
(as indicated) at 37 oC/5% CO2. In some experiments, cells were pre-incubated with 1
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μM KN-62, 0.1 μM AZ10606120 or DMSO (diluent control), or in the presence of 10
μM A-438079 or H2O (diluent control) for 15 min at 37oC/5% CO2 before the addition
of a nucleotide. The cells were then incubated with 0.45 mg/mL MTT solution during
the final four hours of the 24 and 48 h incubations, after which 100 µL solubilisation
solution (10% SDS in 0.01 M HCl) was added and the plates incubated overnight at
37 oC. In some experiments, in the final four hours of the 24 and 48 h incubations, the
cells were suspended in fresh culture media followed by the addition of 0.45 mg/mL
MTT solution and solubilised thereafter. The mean absorbance was measured using a
SpectaMax Plus384 microplate reader (Molecular Devices, Sunnyvale, California,
U.S.A.) at a wavelength of 550 nm and a reference wavelength of 690 nm.
2.9 Measurement of cell death by trypan blue exclusion
Cells (1.5 × 10 4 cells/0.5 mL/well) in their respective culture medium were
seeded in triplicate in 24 well plates and incubated for 24 hours at 37oC/5% CO2. Cells
were then incubated in the absence or presence of nucleotide or 3 µM isatin for 24 or 48
h (as indicated) at 37oC/5% CO2. At the end of 24 and 48 h incubations, aliquots of cells
were mixed with an equal volume of 0.4% trypan blue solution in PBS. The total
numbers of live and dead cells were then counted using a Bright-Line Haemocytometer
(Hausser Scientific, Hersham, Pennsylvania, U.S.A.) according to manufacturer’s
instructions.
2.10 Morphological analysis of cell death
Cells 1.5 × 10 4 cells/0.5 mL/well) in their respective culture medium were
seeded in triplicate in 24-well plates and incubated for 24 hours at 37oC/5% CO2. Cells
were then incubated in the absence or presence of nucleotide or isatin for 24 or 48 h (as
indicated) at 37 oC/5% CO2. At the end of 24 and 48 h incubations, a Leica (Mannheim,
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Germany) DC 500 phase contrast microscope was used to analyse the cells. Images
were captured using Leica Firecam software (Version 1.7.1). Apoptotic cells were
identified according to classified morphological features of apoptotic cells including
blebbing of the membrane, condensation of the nuclei and rounding up of cells
(Kroemer et al., 2005; 2009).
2.11 Presentation of data, statistics and nomenclature
Data is presented as the mean ± standard deviation (SD). Differences between
treatments were compared using either the unpaired Student’s t-test for single
comparisons to control samples or ANOVA for multiple comparisons (using Tukey’s
post test) using Prism 5 for PC version (GraphPad Software, San Diego, California,
U.S.A.) with P < 0.05 considered significant. The nomenclature for P2X7, rather than
P2X7, has been adopted according to recent recommendations (Jarvis and Khakh, 2009;
Collingridge et al., 2009; Harmar et al., 2009).
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Chapter 3: TGF-β1 prevents up-regulation of the P2X7 receptor in
IFN-γ and LPS-treated myeloid leukemic THP-1 monocytic cells
3.1 Results
3.1.1 TGF-β1 prevents the up-regulation of P2X7 expression by IFN-γ and LPS
Differentiation

of

THP-1

cells

with

interferon-gamma

(IFN-γ)

and

lipopolysaccharide (LPS) over three days up-regulates P2X7 expression and function
(Humphreys and Dubyak, 1998). Previous work in our laboratory demonstrated that coincubation with transforming growth factor-β1 (TGF-β1) abrogates cell-surface P2X7
expression and function in IFN-γ and LPS-differentiated THP-1 cells, with a maximal
inhibitory response of 70% at 5 ng/mL and with an IC50 of approximately 0.4 ng/mL
(Tran, 2007; Georgiou and Sluyter, personal communication). Therefore to confirm
these results, THP-1 cells were incubated in the presence of IFN-γ (1000U/mL) and
LPS (1µg/mL) over 72 hours as previously described (Humphreys and Dubyak, 1998),
in the absence or presence of TGF-β1 (10 ng/mL) and the amount of cell-surface P2X7
was measured by immunolabelling with an anti-P2X7 monoclonal antibody (mAb) and
flow cytometry. Cell-surface P2X7 was also examined in THP-1 cells incubated in the
absence of cytokines and LPS (undifferentiated THP-1 cells). Undifferentiated cells
expressed negligible amounts of cell-surface P2X7, whereas cell-surface P2X7 was
significantly upregulated following differentiation with IFN-γ and LPS (mean
fluorescence intensity, MFI of 1.8 ± 0.5 and 28.8 ± 9.6 respectively, P < 0.01; n = 5,
Fig. 3.1 A,B). Consistent with Tran (2007) and Georgiou and Sluyter (personal
communication) co-incubation of THP-1 cells with IFN-γ, LPS and TGF-β1
significantly abrogated cell-surface P2X7 expression (MFI of 10.82 ± 4.2, P < 0.01; n =
5, Fig. 3.1C) compared to THP-1 cells incubated in the presence of IFN-γ and LPS.
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Relative P2X7 Expression

Fig. 3.1 TGF-β1 prevents the up-regulation of P2X7 expression by IFN-γ and LPS in
THP-1 monocytes. THP-1 cells were incubated for 3 days in the (A) absence or (B, C)
presence of 1000 U/mL IFN-γ and 1 μg/mL LPS, and in the (B) absence or (C) presence
of 10 ng/ml TGF-β1. Cells were labelled with FITC-conjugated anti-P2X7 (solid line)
or isotype control (shaded) mAb and 7-amino-actinomycin (7AA)-D, and the relative
cell-surface expression (MFI) was determined by flow cytometry.

Representative

results from five experiments are shown.
3.1.2 TGF-β1 prevents the up-regulation of P2X7 function by IFN-γ and LPS
Next, to confirm that co-incubation of IFN-γ and LPS-differentiated THP-1 cells
with TGF-β1 can abrogate P2X7 function, THP-1 cells were cultured as above and the
ability of ATP and BzATP to induce ethidium+ uptake was measured by flow cytometry.
Differences in the amount of cell-surface P2X7 (Section 3.1.1) corresponded with
differences in ATP-BzATP-induced ethidium+ uptake. Both ATP and BzATP failed to
induce ethidium+ uptake into undifferentiated THP-1 cells with values similar to basal
ethidium+ uptake (Fig. 3.2). As expected ATP induced significant ethidium+ uptake into
differentiated THP-1 cells compared to basal ethidium+ uptake (Fig. 3.2). Moreover, the
most potent P2X7 agonist, BzATP, (North, 2002), induced significantly higher levels of
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ethidium+ uptake into differentiated THP-1 cells compared to basal and ATP-induced
ethidium+ uptake levels (Fig. 3.2). Both ATP- and BzATP-induced ethidium+ uptake
were significantly lower in IFN-γ and LPS-treated THP-1 cells co-incubated with TGFβ1 compared to IFN-γ and LPS-treated THP-1 cells incubated in the absence of TGF-β1.
(Fig. 3.2)

Fig. 3.2 TGF-β1 prevents the up-regulation of P2X7 function by IFN-γ and LPS in
THP-1 monocytes. THP-1 cells were incubated for 3 days in the presence of 1000 U/mL
IFN-γ and 1 μg/mL LPS in the absence or presence of 10 ng/mL TGF-β1, or in the
absence of IFN-γ and LPS. Cells were resuspended in NaCl medium at 37 oC, ethidium +
(25 mM) was added, followed 30 s later by the addition of 1 mM ATP or 200 µM
BzATP. After 5 min, incubations were stopped by addition of MgCl2 medium and
centrifugation, and the ethidium+ uptake (MFI) determined by flow cytometry. Results
are shown as the mean ± SD (n = 3); **P < 0.01 and ***P < 0.001.
To demonstrate that the effect of TGF-β1 on P2X7 function was not limited to
ethidium+ uptake, ATP-induced YO-PRO-12+ uptake in THP-1 cells, resuspended in
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NaCl medium was examined as described (Gudipaty et al., 2001). ATP induced
significant YO-PRO-12+ uptake into IFN-γ and LPS-treated THP-1 cells, but not into
undifferentiated cells (Fig. 3.3). The presence of TGF-β1 during the incubation of THP1 cells with IFN-γ and LPS significantly decreased ATP-induced YO-PRO-1 2+ uptake
(Fig. 3.3).

Fig. 3.3 TGF-β1 prevents the up-regulation of ATP-induced YO-PRO-12+ uptake in
IFN-γ and LPS-treated THP-1 monocytes. THP-1 cells were incubated for 3 days with
1000 U/ml IFN-γ and 1 μg/ml LPS in the absence or presence of 10 ng/ml TGF-β1, or
in the absence of IFN-γ and LPS. Cells were resuspended in NaCl medium containing 1
µM YO-PRO-1 2+, and incubated in the absence or presence of 1 mM ATP at 37 oC for
15 min. Incubations were stopped by addition of NaCl medium containing 20 mM
MgCl2 medium and centrifugation, and the YO-PRO-1 2+ uptake (MFI) determined by
flow cytometry. Results are shown as mean ± SD (n = 3); ***P < 0.001.
Next, ATP-induced interlukin (IL)-1β release from THP-1 cells was examined as
described (Sluyter et al., 2004). Nigericin, which induces IL-1β release independently
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of P2X7 activation, was used as a positive control. ATP induced a small but significant
release of IL-1β from IFN-γ and LPS-treated THP-1 cells, but not undifferentiated cells
(Fig. 3.4). The presence of TGF-β1 during the incubation of THP-1 cells with IFN-γ and
LPS decreased ATP-induced IL-1β release by 79 ± 26%, although this failed to reach
statistical significance (Fig. 3.4). This decrease in ATP-induced IL-1β release was not
due to differences in IL-1β synthesis or release mechanisms between the two groups as
nigericin caused a similar IL-1β release from IFN-γ and LPS-treated cells incubated in
the absence or presence of TGF-β1 (Fig. 3.4).

Fig. 3.4 TGF-β1 prevents the up-regulation of ATP-induced IL-1β release in IFN-γ and
LPS-treated THP-1 monocytes. THP-1 cells were incubated for 3 days with 1000 U/mL
IFN-γ and 1 μg/mL LPS in the absence or presence of 5 ng/mL TGF-β1, or in the
absence of IFN-γ and LPS. Cells were suspended in RPMI-1640 medium containing
0.1% BSA, and incubated in the absence or presence of 3 mM ATP or 20 μM nigericin
for 15 min at 37°C/5% CO2. The samples were centrifuged and the amount of IL-1β in
cell-free supernatants measured by ELISA. Results are shown as mean ± SD (n = 3); *P
< 0.05 and **P < 0.01.
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3.1.3 TGF-β1 prevents the up-regulation of total P2X7 by IFN-γ and LPS
Human monocytes contain a large pool of intracellular P2X7 (Gu et al., 2000),
which traffics to the cell surface during differentiation to macrophages (Gudipaty et al.,
2001). Therefore, to determine if the effect of TGF-β1 in differentiated THP-1 cells is
due to altered P2X7 trafficking or to a decrease in total P2X7 protein, whole lysates of
THP-1 cells were prepared and the amount of P2X7 was examined by immunoblotting.
Actin was included as a loading control. Immunoblotting with an anti-P2X7 polyclonal
antibody (Ab) failed to detect any bands in untreated THP-1 cells despite the presence
of actin (Fig. 3.5). In contrast, this procedure revealed the presence of a major band at
75 kDa, the predicted size of glycosylated P2X7, in IFN-γ and LPS-treated THP-1 cells
incubated in the presence or absence of TGF-β1 (Fig. 3.5). A minor band at 55 kDa
was also detected in these cells (Fig. 3.5). Of note, the intensity of the 75 and 55 kDa
bands were consistently reduced in the IFN-γ and LPS-treated THP-1 cells incubated in
the presence of TGF-β1 compared to IFN-γ and LPS-treated cells incubated in the
absence of TGF-β1, despite the presence of equal amounts of actin (Fig. 3.5).
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Fig. 3.5 TGF-β1 prevents the up-regulation of total P2X7 in IFN-γ and LPS-treated
THP-1 monocytes. Whole lysates of untreated THP-1 cells, as well as of THP-1 cells
incubated for 3 days with 1000 U/mL IFN-γ and 1 μg/mL LPS in the absence or
presence of 10 ng/mL TGF-β1 were separated by electrophoresis, transferred to
nitrocellulose membrane and probed with either (Left panel) anti-P2X7 Ab or (right
panel) anti-actin Ab. Molecular weight markers, detected using StrepTactin-HRP, are
shown in the far left lanes of each blot. Results are representative of three experiments.
3.1.4 TGF-β1 prevents the up-regulation of P2X7 mRNA by IFN-γ and LPS
Incubation of THP-1 cells with IFN-γ and LPS up-regulates P2X7 mRNA
(Humphreys and Dubyak, 1998). Therefore, to determine if the effect of TGF-β1 in
differentiated THP-1 cells is due to a decrease in P2X7 mRNA, RNA was isolated from
THP-1 cells and the amount of P2X7 mRNA examined by RT-PCR. β-actin was
included as a house keeping control and RPMI 8226 myeloma cells were used as
positive control, which express high amounts of functional P2X7 (Farell, 2008). P2X7
mRNA was present in undifferentiated THP-1 cells, and incubation with IFN-γ and LPS
up-regulated P2X7 mRNA expression (Fig. 3.6). In contrast, P2X7 mRNA expression
in IFN-γ and LPS-treated cells incubated in the presence of TGF-β1 was lower than
IFN-γ and LPS-treated cells incubated in the absence of TGF-β1, despite similar
expression of β-actin mRNA (Fig. 3.6).
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Fig. 3.6 TGF-β1 prevents the up-regulation of P2X7 mRNA in IFN-γ and LPS-treated
THP-1 monocytes. (Left panel) P2X7 and (right panel) β-actin mRNA from untreated
THP-1 cells and RPMI 8226 cells, as well as from THP-1 cells incubated for 3 days
with 1000 U/mL IFN-γ and 1 μg/mL LPS in the absence or presence of 10 ng/mL TGFβ1 were amplified by RT-PCR, the products separated on a 2% agarose gel and
visualised using ethidium bromide staining. A negative control for P2X7 primers was
set up by substituting RNA with distilled water. Results are representative of three
experiments.
3.1.5 TGF-β1 prevents the up-regulation of CD86 but not CD14 or MHC class II
by IFN-γ and LPS
Tamai et al (2003) have shown that co-stimulation of undifferentiated THP-1
cells with IFN-γ and LPS markedly enhances cell surface CD14 expression. Therefore,
it was determined if the TGF-β1 effect on THP-1 cells incubated with IFN-γ and LPS
was specific to P2X7 or could also affect other cell-surface receptors. THP-1 cells
incubated with IFN-γ and LPS in the presence or absence of TGF-β1, as well as
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undifferentiated cells were labelled with a panel of mAb and the expression of cellsurface markers examined by flow cytometry. Undifferentiated THP-1 cells expressed
negligible to low levels of cell-surface CD14, CD86 and MHC class II, as well as P2X7
(Fig. 3.7). Differentiation of THP-1 cells with IFN-γ and LPS increased the cell-surface
expression of P2X7, CD14, CD86 and MHC class II (Fig. 3.7). As above (Fig. 3.1), the
presence of TGF-β1 during the incubation of THP-1 cells with IFN-γ and LPS
significantly decreased P2X7 expression (Fig. 3.7). Similarly, TGF-β1 significantly
decreased CD86 expression on cells incubated with IFN-γ and LPS (Fig. 3.7). In
contrast, CD14 and MHC class II expression was similar on IFN-γ and LPS-treated
THP-1 cells incubated in the presence or absence of TGF-β1 (Fig. 3.7).
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Fig. 3.7 TGF-β1 prevents the up-regulation of CD86 but not CD14 or MHC class II in
IFN-γ and LPS-treated THP-1 monocytes. Untreated THP-1 cells, as well as THP-1
cells incubated for 3 days with 1000 U/mL IFN-γ and 1 μg/mL LPS in the absence or
presence of 10 ng/mL TGF-β1, were labelled with fluorochrome-conjugated mAb and
7AAD, and the relative cell-surface expression (MFI) determined by flow cytometry.
Results are expressed as the mean ± SD (n = 5); *P < 0.05, **P < 0.01 and ***P <
0.001.
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3.2 Discussion
P2X7 expression and function can be up-regulated in the human leukemic
monocytic cell line THP-1 upon incubation with IFN-γ and LPS (Humphreys and
Dubyak, 1998 and Humphreys et al., 1998). Using this model of monocyte/macrophage
differentiation, Tran (2007) and Georgiou and Sluyter (personal communication)
demonstrated that TGF-β1 prevents the up-regulation of P2X7 expression and function
(ATP-induced ethidium+ uptake) by IFN-γ and LPS; however the mechanism has never
been elucidated. Results in this chapter confirm that TGF-β1 prevents the up-regulation
of P2X7 in IFN-γ and LPS-treated THP-1 cells. Moreover, results in this chapter
indicated this effect of TGF-β1 was not limited to ethidium+ uptake, as ATP-induced
YO-PRO-12+ uptake and IL-1β release was also impaired in IFN-γ and LPS-treated
THP-1 cells incubated with TGF-β1 compared to IFN-γ and LPS-treated cells incubated
without TGF-β1. Although, it should be noted that the amount of ATP-induced IL-1β
released from THP-1 cells incubated for 3 days with IFN-γ and LPS is lower than the
amount of ATP-induced IL-1β release from THP-1 cells incubated for 3 h with PMA
and then for 6-24 h with LPS (Grahames et al., 1999; MacKenzie et al., 2001) or for 2
days with IFN-γ and then for 4 h with LPS (Gudipaty et al., 2003). The reason for this
difference is unknown, but prolonged (3 day) incubation of THP-1 cells with LPS
and/or possibly IFN-γ may result in the loss of IL-1β prior to ATP or nigericin
incubation. Alternatively, 3-day incubation of THP-1 cells with IFN-γ and LPS may not
induce large amounts IL-1β synthesis.
The mechanism by which TGF-β1 abrogates the up-regulation of cell-surface
P2X7 by IFN-γ and LPS in THP-1 cells has been elucidated. Immunoblotting of whole
cell lysates with anti-P2X7 Ab demonstrated that TGF-β1 prevents the synthesis of the
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total amount of P2X7 protein in differentiated THP-1 cells. Moreover, this reduction in
P2X7 protein paralleled a decrease in P2X7 mRNA expression suggesting that
transcription rather than translation is abrogated by TGF-β1 in THP-1 cells incubated
with IFN-γ and LPS. However, we cannot exclude the possibility that TGF-β1 may be
involved in some post-transcription event such as increased P2X7 mRNA decay, as
TGF-β1 can increase the rate of decay of chemokine mRNA induced by LPS in murine
macrophages (Dai et al., 2003). It appears unlikely that the inhibitory effect of TGF-β1
is due to impaired trafficking of P2X7 as total P2X7 protein amounts were reduced
following TGF-β1 treatment, although impaired trafficking cannot be fully excluded as
an additional, albeit minor, mechanism. The inhibitory effect of TGF-β1 is not due to
increased amounts of a P2X7 variant, which impairs P2X7 expression and function as
observed in some epithelial cell lines (Gordeski, 2009), as immunoblotting revealed a
decrease in both full length P2X7 (75 kDa) and a shorter P2X7 variant (55 kDa). The
reduced P2X7 function following TGF-β1 incubation was also not due to increased
levels of the ecto-ATPDase CD39 (Tran, 2007). THP-1 cells, regardless of treatment,
failed to express cell-surface CD39; however the possibility that other ectonucleotidases
(Yegutkin, 2008) play an ancillary role in the reduced P2X7 function in TGF-β1-treated
THP-1 cells cannot be excluded.
The THP-1 cell line is a well-established model used to study the P2X7 receptor
and its downstream effects. Data in this chapter confirms the presence of functional
P2X7 in THP-1 cells following differentiation with IFN-γ and LPS, as originally
observed by others (Humphreys and Dubyak, 1998; Humphreys et al., 1998). Data in
this chapter also confirms the absence of functional P2X7 in undifferentiated THP-1
cells as observed by others (Humphreys and Dubyak, 1996; 1998). In contrast another
67

group (Aga et al., 2002) has demonstrated the presence of functional P2X7 in
undifferentiated THP-1 cells whereby the most potent P2X7 agonist, BzATP induced
mitogen activated protein kinase activation, NF-κB translocation and IL-1β release. The
reasons for these differences are unknown but may reflect differences in cell lines
between laboratories, differences in the relative sensitivities of the different assays, or
differences in the relative activation thresholds including amounts of cell-surface P2X7
expression required for different P2X7-mediated events. However it should be noted
that BzATP failed to induce significant cation dye uptake and IL-1β release in
undifferentiated THP-1s in my study. The detection of P2X7 mRNA and low to
negligible amounts of cell-surface P2X7, in undifferentiated THP-1 cells in this chapter
suggests these cells may contain low amounts of functional P2X7 but which were
undetectable by the cation uptake and IL-1β release assays used.
The permeability pathways that mediate the passage of large organic ions following
P2X7 activation have not been fully elucidated, although recent data indicates that the
dissociation of non-muscle myosin from the P2X7 complex may be involved in P2X7
pore formation (Gu et al., 2009). In this chapter, ATP induced the uptake of ethidium+
(314 Da) and YO-PRO-1 2+ (375 Da), while previous data from our laboratory
demonstrated that ATP induced ethidium+ but not propidium2+ (415 Da) into
differentiated THP-1 cells (Sluyter, personal communication). These results are similar
to those observed in human lymphocytes (Wiley et al, 1993) and dendritic cells (Sluyter
and Wiley, 2002), but contrasts ATP-induced uptake of propidium2+ uptake in
osteoblasts (Panupinthu et al., 2008) and P2X7-transfected HEK-293 cells (Milius et al.,
2007). The opening of pannexin-1 has also been implicated in the P2X7-mediated
uptake of ethidium+ in macrophages and P2X7-transfected HEK-293 cells (Pelegrin and
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Suprenant, 2006), but the presence of pannexin-1 in THP-1 cells and whether this
hemichannel is permeable to propidium2+ is unknown. Nevertheless our data suggests
that propidium2+ may enter via a different permeability pathway to that of ethidium+, or
that the pore size of the P2X7 permeability pathway may differ between cell types.
In addition to P2X7, IFN-γ and LPS up-regulated the expression of CD14, CD86
and MHC class II in THP-1 cells. Although various inflammatory stimuli can upregulate each of these receptors in THP-1 cells (Tamai et al., 2003; Miyazawa et al.,
2007; Tomoda et al, 1992), in relation to incubation with both IFN-γ and LPS this has
only been previously demonstrated for CD14 (Tamai et al., 2003). Thus, data in this
chapter demonstrates that in addition to CD14, incubation with both IFN-γ and LPS, can
also up-regulate CD86 and MHC class II in THP-1 cells. It should be noted however,
that in two of the five experiments the up-regulation of MHC class II was negligible
despite up-regulation of P2X7, CD14 and CD86. Sub-analysis of the three remaining
experiments showed that incubation with IFN-γ and LPS significantly up-regulated
MHC class II in THP-1 cells, and that co-incubation with TGF-β1 did not abrogate
expression of this cell-surface molecule (results not shown). The null effect of TGF-β1
on CD14 and MHC class II in THP-1 monocytes in the presence of both IFN-γ and LPS
contrasts that observed with macrophages treated with either IFN-γ or LPS alone, where
TGF-β1 inhibits the expression of either CD14 or MHC class II on IFN-γ- or LPStreated macrophages respectively (Imai et al, 2000; Nandan and Reiner, 1997). The
reasons for these differing results are unknown. The action of TGF-β1 however varies
depending on the combination of cytokines within the extracellular environment
(Dennler, Goumans and Dijke, 2005) thus providing a possible explanation for the
differences observed between the various studies, apart from differences in cell type.
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The inhibitory effect of TGF-β1 on P2X7 in IFN-γ and LPS-treated THP-1 cells
suggests that TGF-β1 may impair the expression and function of P2X7 on macrophages
during inflammatory and immune responses. P2X7 activation can stimulate the NALP3
inflammasome to cause the subsequent release of IL-1β from macrophages (Ferrari et
al., 2006). Thus, TGF-β1 released during or after infection may serve to reduce ATPinduced IL-1β release by down-regulating P2X7 in macrophages to limit tissue injury or
to help resolve the immune response. In contrast, the absence of TGF-β1 may allow
maximal P2X7 expression and function to promote ATP-induced IL-1β release during
the immune response. Our findings (Tran, 2007; Georgiou and Sluyter, personal
communication; this chapter) also suggest that aberrant TGF-β1 production may
contribute to immune-related disorders in which P2X7 is involved. For example, the
absence of TGF-β1 may help to maintain ATP-induced IL-1β release in rheumatoid
arthritis where a role for P2X7 has been established (Labasi et al., 2002). Alternatively,
increased TGF-β1 release during infection may down-modulate P2X7 expression in
macrophages resulting in impaired ATP-induced killing of intracellular pathogens. In
this regard, loss of P2X7 function, resulting from polymorphic variations in the P2RX7
gene, results in impaired ATP-induced killing of intracellular Mycobacterium
tuberculosis and Toxoplasma gondi, and increased susceptibility to tuberculosis and
toxoplasmosis respectively (Fernando et al., 2007; Lees et al., 2010) highlighting the
requirement for optimal P2X7 expression and function to control these pathogens.
Moreover, both these pathogens can induce TGF-β1 release to suppress macrophage
activation to allow their survival and to promote disease (Li et al., 2006), suggesting
that down-regulation of P2X7 by this cytokine during infection may provide an
additional mechanism by which these pathogens can evade destruction. Finally, TGF-β1
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may also modulate P2X7 expression and function within the tumour microenvironment.
TGF-β1 can promote and suppress tumour growth by acting on malignant, stromal and
immune cells. Thus it is possible that TGF-β1 may act on any of these cell types
expressing P2X7 to modify the progression of malignant diseases. It will be of future
importance to determine if TGF-β1 can prevent the up-regulation of P2X7 on
macrophages differentiated from primary monocytes, as well as the effect of TGF-β1 on
P2X7 in other normal and malignant cell types.
In conclusion, this study confirms that TGF-β1 can prevent the up-regulation of
P2X7 expression and function by IFN-γ and LPS in THP-1 monocytes, and indicates
that TGF-β1 prevents P2X7 upregulation by preventing the upregulation of P2X7
mRNA and the subsequent synthesis of P2X7. This suggests that TGF-β1 may limit
P2X7-mediated processes during inflammatory and immune responses or P2X7
function in malignant cells.
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Chapter 4: Colon epithelial carcinoma HCT-8 and Caco-2 cells lack
functional P2X7 receptors
4.1 Results
4.1.1 HCT-8 and Caco-2 cells express low levels of P2X7
P2X7 is present in normal and malignant primary epithelial cells of the intestine
(Groschel et al., 1999) and skin (Greig et al., 2003; Georgiou et al., 2005). In addition,
Coutinho-Silva et al (2005) have demonstrated that ATP and BzATP induce death of
the human colon epithelial carcinoma cell lines, HCT-8 and Caco-2 in a manner
characteristic of P2X7, but direct evidence for P2X7 in this process was lacking.
Therefore, to study the presence of P2X7 on these cell lines, HCT-8 and Caco-2 cells
were labelled with anti-P2X7 monoclonal antibody (mAb) and examined by flow
cytometry. Human multiple myeloma RPMI 8226 cells, which express high amounts of
functional P2X7 (Farell, 2008), were used as a positive control. The RPMI 8226 cells
were found to express high levels of P2X7 on the cell-surface compared to the isotype
control (mean fluorescence intensity, MFI of 34.9 ± 4.7 and 5.7 ± 2.8 respectively, P <
0.01; n = 3, Fig. 4.1). In contrast, low levels of cell surface P2X7 were detected on
HCT-8 and Caco-2 cells relative to the isotype control (HCT-8, MFI of 9.2 ± 3.4 and
5.7 ± 1.1 respectively; Caco-2, 13.1 ± 3.9 and 10.3 ± 6.0 respectively; n = 3, Fig. 4.1B,
C).
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Caco-2
B

C

Relative P2X7 expression

Fig. 4.1 HCT-8 and Caco-2 cells express low levels of cell surface P2X7. (A) RPMI
8226 (positive control), (B) HCT-8 and (C) Caco-2 cells were labelled with FITCconjugated anti-P2X7 (solid line) or isotype control (shaded) mAb and 7-aminoactinomycin-D (7AAD), and the relative cell surface expression (MFI) determined by
flow cytometry. Representative results from three experiments are shown.
To determine whether this low amount of P2X7 on HCT-8 and Caco-2 cells
was due to low cell surface P2X7 expression or non-specific binding of the anti-P2X7
mAb, immunoblotting was performed on whole cell lysates of RPMI 8226, HCT-8 and
Caco-2 cells. Immunoblotting of RPMI 8226 cells with an anti-P2X7 polyclonal
antibody (Ab) revealed the presence of a major band at 75 kDa (Fig. 4.2), the predicted
size of glycosylated P2X7. Intense bands were present at 68 and 42 kDa in RPMI 8226
cells (Fig. 4.2), which most likely correspond to non-glycosylated P2X7, and a P2X7
variant or breakdown product. Immunoblotting with the same P2X7 Ab also revealed
the presence of strong 68 and 42 kDa bands in HCT-8 and Caco-2 cells (Fig. 4.2). In
contrast, these cells expressed only a faint band at 75 kDa (Fig. 4.2).
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Fig. 4.2 HCT-8 and Caco-2 cells express low amounts of full-length P2X7. Whole
lysates of RPMI 8226, HCT-8 and Caco-2 cells were separated by electrophoresis,
transferred to nitrocellulose membrane and probed with anti-P2X7 antibody. Molecular
weight markers, detected using StrepTactin-HRP, are shown in the far left lane. Results
representative of four experiments.
4.1.2 P2X7 agonists do not induce ethidium+ uptake in to HCT-8 and Caco-2 cells.
The above results indicate that HCT-8 and Caco-2 cells express low amounts of
P2X7. To determine if these cells express functional P2X7, the ability of ATP to induce
ethidium+ uptake over 5 min into HCT-8 and Caco-2 cells was measured previously as
for THP-1 cells (Chapter 3). RPMI 8226 cells were used as a positive control. As
predicted, ATP induced significant ethidium+ uptake into RPMI 8226 myeloma cells at
5 min compared to basal levels (Fig. 4.3A). In contrast, 5 min incubation with ATP
failed to induce ethidium+ uptake into HCT-8 and Caco-2 cells compared to the basal
levels (Fig. 4.3B,C).
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Fig. 4.3 ATP does not induce ethidium+ uptake into HCT-8 and Caco-2 cells. (A)
RPMI 8226, (B) HCT-8 and (C) Caco-2 cells in NaCl medium containing 25 µM
ethidium+ were incubated at 37 oC for 5 min in the absence (basal) or presence of 1 mM
ATP. Incubations were stopped by addition of MgCl2 medium and centrifugation, and
the ethidium+ uptake (MFI) determined by flow cytometry. Results are shown as the
mean ± SD (n = 3); ***P < 0.001.
It was possible, that 5 min incubation with ATP was insufficient to detect the
functional activity of the low amounts of cell-surface P2X7 present on HCT-8 and
Caco-2 cells. Therefore, cells were incubated in the presence and absence of ATP or the
most potent P2X7 agonist, 2(3’)-O-(4-benzoylbenzoyl) adenosine 5’ triphosphate
(BzATP) over 30 min. Ethidium+ uptake in the absence or presence of the P2X7
agonists, in both the cell lines was variable but tended to increase over time with the
exception of basal ethidium+ uptake in Caco-2 cells (Fig. 4.4). Nevertheless ATP and
BzATP failed to induce significant ethidium+ uptake compared to basal levels at
corresponding time points in either cell type (Fig. 4.4).
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Fig. 4.4 Prolonged incubation with P2X7 agonists do not induce ethidium+ uptake into
HCT-8 and Caco-2 cells. (A) HCT-8 and (B) Caco-2 cells in NaCl medium containing
25 µM ethidium+ were incubated at 37 oC for up to 30 min (as indicated) in the absence
(basal) or presence of 1 mM ATP or 200 µM BzATP. Incubations were stopped by
addition of MgCl2 medium and centrifugation, and the ethidium+ uptake (MFI)
determined by flow cytometry. Results are shown as the mean ± SD (n = 3).

The maximal response and efflux rates of P2X7 to ATP and BzATP are higher
in KCl medium compared to NaCl medium (Stevenson et al., 2009; Wiley et al., 1993).
While, Michel et al. (1999) have previously shown that the potency of BzATP for
human P2X7 is approximately 20-fold higher in sucrose medium compared to NaCl
medium, similar to that used above (Fig. 4.2 and 4.3). Moreover, P2X7 activation can
be detected in malignant cell lines resuspended in sucrose but not NaCl medium
(Alqallaf et al., 2009; Zhang et al., 2007). Therefore, HCT-8 cells were suspended in
KCl or sucrose medium and incubated in the presence and absence of ATP or BzATP,
and the relative levels of ethidium+ uptake over 5 min were measured. Cells in NaCl
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medium were studied as a comparison. ATP and BzATP failed to induce ethidium+
uptake into HCT-8 cells in KCl and sucrose medium, as well as NaCl medium (Fig. 4.5).
NaCl medium

A

KCl medium

B

Sucrose medium

C

Fig. 4.5 P2X7 agonists do not induce ethidium+ uptake into HCT-8 cells in KCl or
sucrose medium. HCT-8 cells in (A) NaCl, (B) KCl or (C) sucrose medium containing
25 µM ethidium+ were incubated at 37ºC for 5 min in the absence (basal) or presence of
1 mM ATP or 200 µM BzATP. Incubations were stopped by addition of MgCl2 medium
and centrifugation and the ethidium+ uptake (MFI) was determined by flow cytometry.
Results are shown as the mean ± SD (n = 3).
Since, neither ATP nor BzATP could induce ethidium+ uptake into HCT-8 cells
in KCl or sucrose medium over 5 min, the ability of ATP and BzATP to induce
ethidium+ uptake into HCT-8 and Caco-2 cells over 30 min was examined. Both basal
and nucleotide-induced ethidium+ uptake into both cell lines was variable and no regular
trend was observed (Fig. 4.6). Moreover, both ATP and BzATP failed to induce
significant ethidium+ uptake in HCT-8 and Caco-2 cells in sucrose medium over 30 min
compared to basal levels (Fig. 4.6).
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Fig. 4.6 ATP and BzATP do not induce ethidium+ uptake in HCT-8 and Caco-2 cells in
sucrose medium over extended incubation. (A) HCT-8 and (B) Caco-2 cells in sucrose
medium containing 25 µM ethidium+ were incubated at 37ºC for over 30 min in the
absence (basal) or presence of 1 mM ATP or 200 µM BzATP. Incubations were stopped
by addition of MgCl2 medium and centrifugation, and the ethidium+ uptake (MFI) was
determined by flow cytometry.. Results are shown as the mean ± SD (n = 3).
Activation of P2X7 is impaired in the presence of extracellular Ca2+ (Virginio et
al., 1997). Of note, the sucrose medium of Michel et al (1999) and as used above
contains 0.5 mM CaCl2. Therefore, ATP- and BzATP-induced ethidium+ uptake was
assessed in HCT-8 and Caco-2 cells resuspended in sucrose medium without Ca2+.
Again basal and nucleotide-induced ethidium+ uptake was variable over three
independent experiments and no regular trend was observed. Moreover, both ATP and
BzATP failed to induce significant ethidium+ uptake in HCT-8 and Caco-2 cells in
sucrose medium over 30 min compared to basal levels (Fig. 4.7).
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Fig. 4.7 ATP and BzATP do not induce ethidium+ uptake in HCT-8 and Caco-2 cells in
sucrose medium without Ca2+. (A) HCT-8 and (B) Caco-2 cells in sucrose medium
(without Ca2+) containing 25 µM ethidium+ were incubated at 37ºC for over 30 min in
the absence (basal) or presence of 1 mM ATP or 200 µM BzATP. Incubations were
stopped by addition of MgCl2 medium and centrifugation and the ethidium+ uptake
(MFI) was determined by flow cytometry. Results are shown as the mean ± SD (n = 3).
4.1.3. P2X7 agonists do not induce death of HCT-8 and Caco-2 cells
Using a MTT (tetrazolium-based colourimetric) cell viability assay,
Coutinho-Silva et al (2005) demonstrated that ATP could induce death of HCT-8 and
Caco-2 cells, although a direct role for P2X7 in this process was not established.
Nevertheless, the possibility remained that P2X7 activation induces cell death but not
ethidium+ uptake in these cells, or that the MTT assay may be a more sensitive assay
than ethidium+ uptake in detecting functional P2X7. Therefore, ATP- and BzATPinduced death of HCT-8 and Caco-2 cells over 24 and 48 h incubation was assessed
using the MTT assay as described (Coutinho-Silva et al., 2005). The MTT assay
provides an indirect measure of cell death by measuring cell numbers (derived from
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absorbance readings of formazan crystal formation converted from MTT by
metabolically active cells). Incubation of HCT-8 and Caco-2 cells with either agonist
for 24 and 48 h failed to induce cell death in to HCT-8 and Caco-2 cells (Fig. 4.8A,C).
In one out of three experiments, BzATP induced low but insignificant levels of death in
Caco-2 cells, at 48 h, compared to the basal (results not shown). The results however
did not follow a consistent pattern; all three independent experiments gave variable
results. Therefore, in an alternative more conventional protocol after incubation with
nucleotide, the culture medium was not replaced, prior to the addition of MTT. Similar
results however were observed. Both ATP and BzATP failed to induce significant cell
death in HCT-8 and caco-2 cells at both the time points (Fig. 4.8B,D). Again the three
set of results were found to be quite variable.
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Fig. 4.8 ATP and BzATP do not induce cell death in HCT-8 and Caco-2 cells. (A, B)
HCT-8 cells and (C, D) Caco-2 cells in complete culture medium were incubated in the
absence (basal) or presence of 1 mM ATP or 200 µM BzATP at 37 oC/5% CO2 for 24
hrs and 48 hrs. (A,C) At the end of 24 and 48 hours, the culture media of individual
wells was substituted with 100 μl of fresh culture medium before MTT addition. (B,D)
At the end of 24 and 48 hours, MTT was added directly to the culture media without
any substitution. (A-D) Cells were incubated with MTT for 4 h, before overnight
incubation with solubilization solution at 37oC. Absorbances were then read at 550 and
690 nm. Results are mean absorbances (A550

nm-A690 nm)

± SD of triplicate wells;

representative results from two experiments are shown.
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4.1.4 IFN-γ does not upregulate P2X7 in HCT-8 cells
During the course of this thesis, Welter-Stahl et al (2009) showed that P2X7 can
be upregulated in HCT-8 cells following incubation with an interferon-gamma (IFN-γ).
Therefore, in an attempt to upregulate P2X7 expression and/or function in HCT-8 cells,
cells were incubated in the presence of increasing concentrations of IFN-γ, as described
(Welter-Stahl et al., 2009), and cell-surface P2X7 expression and BzATP-induced
ethidium+ uptake measured. IFN-γ failed to upregulate either P2X7 expression or
function in HCT-8 cells (Fig. 4.9A,B).
A

B

Fig. 4.9 IFN-γ does not upregulate P2X7 expression and function in HCT-8 cells. HCT8 cells were cultured for 3 days in 5 mL complete media in increasing concentrations of
IFN-γ (as indicated). The cells were harvested and analysed for (A) cell-surface P2X7
expression (as described in Fig. 4.1) and (B) 200 µM BzATP-induced ethidium+ uptake
(as described in Fig. 4.3). Relative P2X7 expression is shown as the difference in
binding between P2X7 and isotype control. Results are shown as the mean ± SD (n = 3).
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4.2 Discussion
The P2X7 receptor is suggested to play an important role in the regulation of
epithelial cell growth (Gordeski, 2009). Its expression has been associated with both
the death and proliferation of human epithelial uterine cells (ectocervical, endocervical
and endometrial) as a result of direct activation by ATP (Wang et al., 2004; 2005; Zhou
et al., 2006). The presence of functional P2X7 has also been identified on human basal
and squamous cell carcinomas (Greig at al., 2003). In contrast, functional P2X7 on
epithelial cells of the gastrointestinal system has not been clearly characterized.
Coutinho-Silva et al (2005) demonstrated that ATP and BzATP induced death of the
human colon epithelial carcinoma cell lines, HCT-8 and Caco-2 in a manner
characteristic of P2X7 activation but a direct role for P2X7 in this process was not
established. Data presented in this chapter demonstrates P2X7 agonists fail to induce
ethidium+ uptake and death in HCT-8 and Caco-2 cells suggesting that these cells fail to
express functional P2X7.
The lack of functional P2X7 in these cell lines could not be attributed to a
technical deficiency in the ethidium+ uptake assay, as both the P2X7 agonists, ATP and
BzATP induced high levels of ethidium+ uptake into RPMI 8226 cells. Moreover
incubation of HCT-8 cells with increasing concentrations of IFN-γ (Welter-Stahl et al,
2009). failed to increase the ability of BzATP to induce ethidium+ uptake or increase
cell-surface P2X7 expression.
However, since ATP-induced ethidium+ uptake assays measure P2X7 pore
formation but not P2X7 channel opening (Wiley et al., 1998), we cannot exclude the
possibility that the epithelial carcinoma cell lines tested in my study express low levels
of the P2X7 channel, but lack the capacity to open the P2X7 pore. Consistent with this,
Coutinho-Silva et al (2005) demonstrated that both ATP and BzATP can induce Ca2+
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fluxes into HCT-8 and Caco-2 cells, and that the P2X7 antagonists, KN-62 and oxidised
ATP, could partially impair these responses. Our laboratory however lacked the
techniques to explore Ca2+ fluxes in HCT-8 and Caco-2 cells, but was considered not
worth pursuing due to a lack of functional P2X7 responses with the MTT assay.
Moreover, neither ATP nor BzATP could induce ethidium+ uptake in HCT-8 or Caco-2
cells in KCl or sucrose medium nominally free of both Na+ and Ca2+ ions, both of which
can partially impair P2X7 function (Wiley et al., 1993; Michel et al., 1999; Stevenson
et al., 2009).
Use of the MTT assay was unable to confirm the presence of functional P2X7 on
HCT-8 and Caco-2 cells, and was unable to replicate the findings of Coutinho-Silva et
al., 2005). These authors showed that low concentrations of ATP (10 µM) stimulated
proliferation and high ATP concentrations (1 mM) induced death in HCT-8 and Caco-2
cells. In contrast, data in this chapter showed that ATP (1 mM) and the most potent
P2X7 agonist, BzATP (200 µM) failed to induce significant levels of death in either of
the cell lines. Reasons for these differences between the studies in this chapter to that of
Coutinho-Silva (2005) are not readily apparent. Cells were maintained in identical
culture medium, except that Caco-2 cells were maintained in medium containing 20%
foetal calf serum according to the cell supplier’s instruction. Moreover, the MTT assay
employed was the same in both studies. Although performing the MTT assay with a
more conventional step, i.e. not substituting the culture medium before MTT addition, I
also failed to observe ATP- or BzATP-induced cell death. Moreover, this same MTT
assay could be used to demonstrate that ATP and BzATP could induce death of the
RPMI 8226 cell line, and that this ATP-induced cell death could be blocked by the
P2X7 antagonists, KN-62 and A-438079 (Appendix I). One possible explanation for the
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differences between my study and that of Coutinho-Siva and colleagues is the origin of
the epithelial cell lines. Coutinho-Silva et al (2005) obtained HCT-8 and Caco-2 cells
from the American Tissue Culture Collection, while the cells obtained in my study were
from the European Collection of Cell Cultures. Another possible explanation between
these two studies is that the HCT-8 and Caco-2 cell lines used in my study, expressed
higher amount of a P2X7 variant, which may inhibit P2X7 trafficking or function,
compared to the cell lines used by Coutinho-Silva et al (2005). However, CoutinhoSilva and colleagues (2005) did not report immunoblotting data in their study, making
any direct comparisons difficult. Nevertheless, the relatively high amounts of a nonglycosylated P2X7 (68 kDa) and a possible 42 kDa P2X7 variant, compared to the fulllength, glycosylated P2X7 (75 kDa) support this possible explanation. As discussed
below however this 42 kDa is not the P2X7-j variant and it will be of future importance
to characterise this band further. Coutinho-Silva et al (2005) found that the time course
of ATP-induced cell death was much longer (24-48 h) in HCT-8 cells compared with
other cells such as macrophages and dendritic cells (6 h) that express P2X7 at higher
levels (Coutinho-Silva et al., 1999; 2001). Therefore, longer ATP incubation times or
even higher concentrations of ATP could be considered with the HCT-8 and Caco-2
cells in our laboratory to further exclude the determine if these cell lines express
functional P2X7 and are sensitive to P2X7-induced cell death.
Immunolabelling with an anti-P2X7 mAb revealed the presence of low levels of
cell-surface P2X7 on HCT-8 and Caco-2 cells. Immunoblotting demonstrated that fulllength P2X7 was present in low amounts. Full length P2X7 (75 kDa) was present only
as a faint band in both HCT-8 and Caco-2 cells, which corresponds to the weak
expression of P2X7 mRNA in HCT-8 and Caco-2 cells (Coutinho-Silva et al., 2005).
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Cancer epithelial cells express high levels of micro-RNAs miR-150 and miR-186 which
stimulates degradation of the P2X7 transcript (Zhou et al., 2008), providing a possible
reason for low P2X7 protein in HCT-8 and Caco-2. Alternatively, over-expression of
the epidermal growth factor receptor may reduce P2X7 expression in HCT-8 and Caco2 cells (Wang et al., 2005; Sibilia et al., 2007). Strong bands reactive with anti-P2X7
Ab were detected at 68 and 42 kDa. The 68 kDa band was most likely the nonglycosylated form of P2X7, while the 42 kDa band was most probably an unknown
P2X7 variant or a breakdown product. This 42 kDa band was not however the P2X7-j
variant, also 42 kDa in size and found in cancer epithelial cells (Feng et al., 2006), as
this variant lacks the C-terminus and hence the peptide sequence (residues 576-595) to
which the anti-P2X7 Ab was raised against. Our findings relating to HCT-8 and Caco-2
cells corresponds to findings in HeLa cells in which P2X7 mRNA and P2X7 protein
was detected but also in which ATP did not elicit pore opening nor induce apoptosis,
the two hallmarks of functional P2X7 expression (Welter-Stahl et al., 2009).
Data in this chapter (and Appendix I) confirms that the human multiple
myeloma RPMI 8226 myeloma cell line express functional P2X7. Our laboratory has
previously shown that these cells express cell-surface P2X7 by immunofluorescence
labelling and flow cytometry (Farrell, 2008). The P2X7 immunoblotting data, as well as
the immunofluorescence labelling data, presented in this chapter and the P2X7 RT-PCR
data (chapter 3) confirms the presence of P2X7 in these cells. Moreover, previous data
from our laboratory, has shown that P2X7 activation induces ethidium+ uptake, CD23
shedding and cell death in these cells, with the latter detected by Annexin-V binding
and 7AAD uptake to detect phosphotidylserine exposure and loss of membrane integrity
(Farrell, 2008). Again the ethidium+ uptake data (this chapter) and the MTT results
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(Apendix A1.2) confirm that P2X7 activation can induce cation uptake and cell death in
RPMI 8226 cells. Others have reported that P2X7 activation can induce cation uptake
and cell death in normal and chronic lymphocytic leukemia (CLL) and B-lymphocytes
(Adinolfi et al., 2002; Wiley et al., 2002; Gu et al., 2000). However the physiological
and pathophysiological roles of P2X7 in normal and malignant B-lymphocytes remain
obscure. To the best of our knowledge there have been no reports of defects in Blymphocyte mediated responses in P2X7 knockout mice (Chessell et al., 2005; Solle et
al., 2001). Moreover, defects in B-lymphocyte function have not been attributed to
altered disease outcomes in models of inflammatory or immune-mediated disorders in
these mice (Chen and Brosnan, 2006). Both enhanced P2X7-induced cell proliferation,
due to high P2X7 amounts (Adinolfi et al., 2002), and defects in P2X7-induced cell
death, due to the Glu496Ala loss-of-function polymorphism (Wiley et al., 2002;
Thunberg et al., 2002), have been postulated to alter disease outcomes in CLL (Virgilio
and Wiley, 2002), however neither hypothesis has been substantiated by additional data
(Sellick et al., 2004). Moreover, the Glu496Ala polymorphism is not associated with
disease outcomes in multiple myeloma (Paneesha et al., 2006). However, it should be
noted that this loss-of-function polymorphism reduces P2X7 function by approximately
50% in heterozygous dosage (Gu et al., 2001), but does not inhibit P2X7 channel
function (Boldt et al., 2003) nor completely impairs P2X7 function in homozygous
dosage (Sluyter et al., 2004). Thus, the possibility remains that P2X7 may still play a
role in B-lymphocyte malignancies independently of this polymorphic variation.
In conclusion, this study demonstrates that P2X7 agonists do not induce
ethidium+ uptake into or death of the epithelial colon carcinoma cell lines, HCT-8 and
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Caco-2. It will be of future interest to characterise the presence of he potential 42 kDa
P2X7 variant f in these cell lines.
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Chapter 5: P2X7 receptor activation induces death of myeloid
leukemic KG-1 cells
5.1 Results
5.1.1 KG-1 cells express P2X7
KG-1 cells are a human myeloid leukemic cell line which can be differentiated
into macrophages and dendritic cells (Baroni et al., 2007), however it is not known if
this cell line expresses functional P2X7. Therefore, to determine the presence of P2X7
on the KG-1 cell line, cells were labelled with an anti-P2X7 monoclonal antibody (mAb)
and examined by flow cytometry. As previously (Chapter 4), RPMI 8226 myeloma cells
were used as a positive control. RPMI 8226 cells were found to express significantly
high levels of P2X7 on the cell-surface compared to the isotype control (mean
fluorescence intensity, MFI of 24.9 ± 3.5 and 5.4 ± 1.0 respectively, P < 0.01; n = 3,
Fig. 5.1A). KG-1 cells were also found to express significant levels of cell-surface
P2X7 compared to the isotype control (MFI of 4.8 ± 0.3 and 1.6 ± 0.1 respectively, P <
0.01; n = 3, Fig. 5.1B), although the amount of cell-surface P2X7 was 6-fold lower
compared to RPMI 8226 cells. However it should be noted that this comparison in
P2X7 expression between cell types was based on fold differences relative to the
respective isotype mAb labelling for each cell type, thus the comparisons are only semiquantitative.
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Relative P2X7 expression

Fig.5.1 KG-1 cells express cell-surface P2X7. (A) RPMI 8226 (positive control) and (B)
KG-1 cells were labelled with Alexa Fluor 647-conjugated anti-P2X7 (solid line) or
isotype control (shaded) mAb and 7-amino-actinomycin-D (7AAD), and the relative
cell surface expression (MFI) determined by flow cytometry. Representative results
from three experiments are shown.
To determine whether this low amount of P2X7 on KG-1 cells was due to low
cell-surface P2X7 expression or non-specific binding of the anti-P2X7 mAb,
immunoblotting was performed on whole cell lysates of RPMI-8226 and KG-1 cells.
Immunoblotting with an anti-P2X7 polyclonal antibody (Ab) revealed the presence of a
major band at 75 kDa in RPMI 8226 cells (Fig. 5.2), the predicted size of P2X7. The 75
kDa band was also present in KG-1 cell (Fig. 5.2)s, however the band intensity in these
cells was much lower compared to RPMI 8226 cells.
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Fig. 5.2 P2X7 protein is present in KG-1 cells. Whole lysates of RPMI 8226 and KG-1
cells were separated by electrophoresis, transferred to nitrocellulose membrane and
probed with anti-P2X7 antibody. Molecular weight markers, detected using
StrepTactin-HRP, are shown in the far left lane. Results representative of three
experiments are shown.
To confirm the presence of P2X7 mRNA in KG-1 cells, RNA was isolated from
KG-1 cells, as well as from RPMI 8226 cells and analysed by RT-PCR. A PCR product
of 544 bp was observed in both cell lines (Fig. 5.3) and this product corresponded to the
predicted size of P2X7. Similar to the pattern observed with immunofluorescence
labelling and immunoblotting, the expression of P2X7 mRNA in KG-1 cells was much
lower compared to that of RPMI-8226 cells.
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Fig. 5.3 P2X7 mRNA is present in KG-1 cells. P2X7 mRNA from RPMI 8226 and KG1 cells were amplified by RT-PCR, the products separated on a 2%agarose gel and
visualised using ethidium bromide staining. Results representative of three experiments
are shown.
5.1.2 KG-1 cells express functional P2X7
To determine if KG-1 cells express functional P2X7, cells were incubated in
NaCl medium in the presence or absence of ATP or the most potent P2X7 agonist,
2(3’)-O-(4-benzoylbenzoyl) adenosine 5’ triphosphate (BzATP), for up to 30 min and
the relative levels of ethidium+ uptake were measured at 5 min intervals by flow
cytometry. ATP failed to induce significant levels of ethidium+ uptake in KG-1 cells at
all time points compared to basal levels at corresponding time points (Fig. 5.4). In
contrast, BzATP induced significant levels of ethidium+ uptake at 15, 20 and 30 min
compared to corresponding basal levels (Fig. 5.4). BzATP did not induce significant
ethidium+ uptake at earlier time points (Fig. 5.4). The highest level of BzATP-induced
ethidium+ uptake was at 30 min, although this was found to be more variable than at 20
min. Thus, the 20 min time point was used for subsequent studies.
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Fig. 5.4 BzATP but not ATP induces ethidium+ uptake into KG-1 cells. KG-1 cells in
NaCl medium containing 25 µM ethidium+ were incubated at 37ºC for over 30 min in
the absence (basal) or presence of 1 mM ATP or 200 µM BzATP. Incubations were
stopped by addition of MgCl2 medium and centrifugation and the ethidium+ uptake
(MFI) was determined by flow cytometry. Results are shown as mean ± SD (n = 3); *P
< 0.05 and **P< 0.01.
As mentioned previously (Section 4.1.3), the potency of BzATP for P2X7 is
approximately 20-fold higher in sucrose medium compared to NaCl medium (Michel et
al., 1999), and that the maximal response and efflux rates of the P2X7 receptor to
BzATP and ATP are higher in KCl medium as compared to NaCl medium (Wiley et al.,
2004; Stevenson et al., 2009). Also as discussed previously (Section 4.1.3), Ca2+ was
omitted from the sucrose medium. Therefore, both ATP- and BzATP-induced ethidium+
uptake in to KG-1 cells was examined in cells resuspended in KCl medium or sucrose
medium (without Ca2+). NaCl medium was included as a comparison. As above (Fig.
5.4), ATP failed to induce significant ethidium+ uptake into cells in NaCl medium
compared to basal levels (Fig. 5.5A). However, BzATP also failed to induce significant
ethidium+ uptake (Fig. 5.5A) contrasting previous results (Fig. 5.4). In contrast, both
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ATP and BzATP induced significant ethidium+ uptake in KCl and sucrose medium
compared to basal levels of ethidium+ uptake in their respective media (Fig. 5.5B,C).
Moreover, in either of these media BzATP-induced ethidium+ uptake was
approximately two-fold higher than ATP-induced ethidium+ uptake.
A

NaCl medium

B

KCl medium

C

Sucrose medium

Fig. 5.5 ATP and BzATP induce ethidium+ uptake in KCl and sucrose medium but not
in NaCl medium. KG-1 cells in NaCl or KCl medium or sucrose medium (without Ca2+)
containing 25 µM ethidium+ were incubated at 37ºC for 20 min in the absence (basal) or
presence of 1 mM ATP or 200 µM BzATP. Incubations were stopped by addition of
MgCl2 medium and centrifugation and the ethidium+ uptake (MFI) was determined by
flow cytometry. Ethidium+ uptake is expressed as MFI. Results are shown as mean ±
SD (n = 3); *P < 0.05, **P < 0.01 and ***P< 0.001.
5.1.3 ATP induces ethidium+ uptake in a concentration dependant manner in KG-1
cells
To determine if the ATP-induced ethidium+ uptake into KG-1 cells was
mediated by P2X7, KG-1 cells in sucrose media (without Ca2+) were first incubated
with increasing concentrations of ATP and the relative amounts of ethidium+ uptake
were measured. ATP induced ethidium+ uptake in KG-1 cells in a concentrationdependent manner, with a maximal uptake at 100 µM ATP and with an EC50 of 8.7 (±
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2.3) mM (Fig. 5.6). These values are approximately 3- and 10-fold lower respectively,
than those obtained for recombinant P2X7 in transfected cells (Donnelly-Roberts, 2009)
and native P2X7 in primary cells and cell lines (Jarvis and Khakh, 2009).

Fig. 5.6 ATP induces ethidium+ uptake in a concentration-dependant manner in KG-1
cells. KG-1 cells in sucrose medium (without Ca2+), containing 25 mM ethidium+ were
incubated at 37oC for 20 min in the presence of increasing ATP concentrations as
indicated. Incubations were stopped by addition of MgCl2 medium and centrifugation,
and the ethidium+ uptake determined by flow cytometry. Ethidium+ uptake is expressed
as percent maximum response to 100 µM ATP. Results are shown as mean ± SD (n = 3).
5.1.4 P2X7 agonists as well as the non-P2X7 agonist, αβmeATP, induces ethidium+
uptake in to KG-1 cells
P2X7 is activated by BzATP and ATP and to a lesser extent by adenosine 5'-O[3-thiotriphosphate] (ATP-γ-S) but not by α-β-methyl ATP (αβmeATP), adenosine
diphosphate (ADP) or uridine triphosphate (UTP) (Bianchi et al. 1999; DonnellyRoberts et al., 2009; Ralevic and Burnstock 1998; Surprenant et al., 1996). Therefore to
further explore the pharmacology of the nucleotide-induced ethidium+ uptake into KG-1
cells, cells in sucrose medium (without Ca2+) were incubated in the absence or presence
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of a panel of nucleotides, (each used at 100 µM) and ethidium+ uptake measured. Both
ATP and BzATP induced the highest amounts of ethidium+ uptake in to KG-1 cells with
amounts significantly greater than basal ethidium+ uptake (Fig. 5.7) ATP-γ-S and αβmethyl ATP also induced significant amounts of ethidium+ uptake into KG-1 cells, but
to a lesser extent than that of ATP or BzATP. ADP and UTP failed to induce significant
ethidium+ uptake in KG-1 cells with amounts similar to the basal ethidium+ uptake (Fig.
5.7). Thus, as for the ATP concentration response, the agonist profile for ethidium+
uptake into KG-1 cells is atypical of P2X7 compared to this receptor in other cell types.

Fig. 5.7 KG-1 cells exhibit an agonist profile atypical of P2X7. KG-1 cells in sucrose
medium (without Ca2+) containing 25 mM ethidium+ were incubated at 37oC for 20 min
in the absence or presence of ATP, BzATP, αβmethylATP ATPγS, ADP and UTP (all
100 µM) at 37oC. Incubations were stopped by addition of MgCl2 medium and
centrifugation, and the ethidium+ uptake (MFI) determined by flow cytometry. Results
are shown as mean ± SD (n = 3); *P < 0.05 and ***P < 0.001.
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5.1.5 P2X7 antagonists impair ethidium+ uptake assay in KG-1 cells
To further determine if nucleotide-induced ethidium+ uptake into KG-1 cells
may be mediated by P2X7, cells in sucrose medium were incubated in the presence of
P2X7 antagonists, KN-62, A-438079 and AZ10606120, or DMSO or H2O diluent
control (as indicated). Pre-incubation of cells with 1 μM KN-62 or 0.1 μM AZ10606120
significantly inhibited 0.1 mM ATP-induced ethidium+ uptake by 77% and 100%
respectively compared to the corresponding controls (Fig. 5.8A). Similarly A-438079
significantly inhibited ATP-induced ethidium+ uptake in KG-1 cells by 100% to the
corresponding control (Fig. 5.8B). Basal ethidium+ uptake either in the presence of each
antagonist or diluents control was similar (Fig. 5.8). These results indicate that ATPinduced ethidium+ uptake involved P2X7 activation.
A

B

Fig. 5.8 P2X7 antagonists impair ATP induced ethidium+ uptake in to KG-1 cells. KG-1
cells in sucrose medium (without Ca2+) were pre-incubated at 37ºC for 15 min in (A) the
presence of DMSO diluents, 1 µM KN-62, or 0.1 μM AZ10606120; (B) the presence of
H2O diluent or 10 µM A-438079, and (A, B) then with 25 µM ethidium+ in the absence
(basal) or presence of 100 µM ATP at 37ºC for 20 min. Incubations were stopped by
addition of MgCl2 medium and centrifugation, and ethidium+ uptake (MFI) determined
by flow cytometry. Results are shown as mean ± SD (n = 3); *P < 0.05 and ***P <
0.001.
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5.1.6 ATP reduces numbers of KG-1 cells
Next the MTT assay was used to determine if ATP induces death of KG-1 cells.
The cytotoxic compound, 5,7-dibromo-N-(p-hydroxymethylbenzyl)isatin (isatin) (Vine
et al., 2007) was used as a positive control. KG-1 cells in the absence or presence of
ATP or isatin for 24 or 48 hours, and the relative cell number (expressed as absorbance)
was determined. Incubation of KG-1 cells in the presence of 100 µM ATP or 3 µM
isatin for 24 h significantly reduced the cell numbers by 44% and 66% respectively
compared to cells incubated in the absence of agonist (Fig. 5.9). ATP- and isatininduced cell death was more pronounced at 48 h, wherein a 51% and 61% reduction in
cell numbers was observed compared to the untreated KG-1 cells (Fig. 5.9).

Fig. 5.9 ATP reduces numbers of KG-1 cells. KG-1 cells in complete culture medium
were incubated in the absence (basal) or presence of 100 µM ATP or 3 µM isatin at
37ºC/5%/CO2 for 24 hr or 48 hr. MTT was added during the final 4 hr, before overnight
incubation with solubilisation solution at 37ºC. Absorbances were then read at 550 nm
and 690 nm. Results are mean absorbances (A550nm- A690nm) ± SD of (n = 3); *** P <
0.001.
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5.1.7 P2X7 antagonists impair the ATP-induced reduction of KG-1 cell numbers
Next to determine whether the reduction in cell numbers by ATP was mediated
by P2X7, KG-1 cells were pre-incubated in either the presence of the P2X7 antagonists,
KN-62, AZ10606120 or A-438079, or DMSO or water diluent control (as indicated) for
24 or 48 h, and the relative cell number measured using the MTT assay. Similar to
above (Fig. 5.9), 24 or 48 h incubation with ATP reduced KG-1 cell numbers (Fig.
5.10A,B). Pre-incubation of KG-1 cells with 1 μM KN-62 significantly inhibited the
ATP-induced reduction in relative cell numbers by 68% and 78% at 24 and 48 h
respectively (Fig. 5.10A). Similarly pre-incubation with 0.1 µM AZ10606120
significantly inhibited the ATP-induced reduction in cell numbers by 64% and 80% at
24 and 48 h respectively (Fig. 5.10A). In the absence of ATP the cell numbers were
similar to those in the presence of DMSO, KN-62 or AZ10606120 (Fig. 5.10A). In
contrast, A-438079, in the absence of ATP significantly reduced cell numbers at 24 and
48 h respectively (Fig. 5.10A). This reduction in cell number by A-438079 was also
significantly reduced in the presence of ATP (Fig. 5.10A). Thus, A-438079 could not be
used to determine if P2X7 mediated the ATP induced reduction in cell numbers.
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Fig. 5.10 P2X7 antagonists, KN-62 and AZ10606120 impair ATP-induced reduction in
KG-1 cell numbers. KG-1 cells in complete culture medium were pre-incubated at 37ºC
for 15 min in (A) the presence of DMSO, 1 µM KN-62 or 0.1μM AZ10606120 or (B)
presence of H2O or 10 µM A-438079, and (A, B) then in the absence or presence of 100
µM ATP at 37ºC/5%/CO2 for 24 or 48 hr. (A, B) MTT was added during the final 4 hr,
before overnight incubation with solubilisation solution at 37ºC. Absorbances were then
read at 550 nm and 690 nm Results are mean absorbances (A550nm- A690nm) ± SD of
triplicate wells; *P < 0.05, **P < 0.01 and ***P < 0.001. Results representative of three
experiments are shown.
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5.1.8 ATP induces death of KG-1 cells
As outlined in Section 4.1.8, the MTT assay is an indirect measure of cell death.
Therefore, to determine if the reduction in KG-1 cell numbers observed above was a
result of cell death or impaired cell proliferation, KG-1 cells were incubated in the
absence or presence of ATP or isatin for 24 or 48 h, and the percent cell viability
assessed by trypan blue exclusion. In addition, the cells were viewed under a light
microscope for morphological analysis. Apoptotic cells were identified using
morphological criteria, including condensation of nuclei and shrinkage of cytoplasm
(Kroemer G., et al, 2005; 2009). Incubation of KG-1 cells with 0.1 mM ATP or 3 µM
isatin for 24 h significantly increased the percentage of dead cells by 4- and 14-fold
respectively (Fig. 5.11A). Similarly, 48 h incubation with ATP and isatin increased the
percentage of dead cells by 5- and 14-fold respectively (Fig. 5.11A). Morphological
analysis demonstrated the presence of apoptotic cells following all treatments (Fig.
5.11B). Apoptotic cells were identified on the basis of rounding up of cells, membrane
blebbing, shrinkage, DNA fragmentation and condensation of the nuclei of cells.
Untreated KG-1 cells however predominantly displayed typical cell morphology of a
heterogeneously shaped cell population (Fig. 5.11B). In contrast, more apoptotic cells
were visible in cultures incubated in the presence of ATP or isatin for 24 or 48 h (Fig.
5.11B)
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Fig 5.11 ATP induces death of KG-1 cells. (A,B) KG-1 cells in complete culture
medium were incubated in the presence and absence of 100 µM ATP or 3 µM isatin
37ºC/5%/CO2 for 24 or 48 hr. (A) Aliquots of cells were resuspended in an equal
volume of 0.4% trypan blue solution for 3 min and counted in a haemocytometer. The
total numbers of viable and dead cells were then estimated, and expressed as percentage
of dead cells. Results are shown as mean ± SD (n = 3); ***P < 0.001. (B) KG-1cells in
the original plated wells were examined using a phase contrast microscope. Scale bar is
equal to 10 µm. Results are representative of three experiments.
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5.2 Discussion
Zhang et al, 2004 have previously shown that the KG-1 variant cell line, KG1a,
express functional P2X7 but the presence of P2X7 on the parental cell line KG-1 had
not been investigated. Results in this chapter demonstrate that the myeloid leukemic cell
line, KG-1, express functional P2X7 with an atypical pharmacological profile. Multiple
evidences

established

that

these

cells

express

functional

P2X7.

First,

immunofluoresence labelling, immunoblotting and RT-PCR demonstrated that KG-1
cells express P2X7 protein and mRNA. Second, the P2X7 agonists, ATP and BzATP
(Bianchi et al., 1999; Donnelly-Roberts et al., 2009), induced ethidium+ uptake into
these cells. Third, the far-less potent P2X7 agonist, ATP-γ-S (Suprenant et al., 1996;
Wiley et al., 1993) also induced partial ethidium+ uptake, while neither ADP nor UTP,
well known non-P2X7 agonists (Jarvis and Khakh, 2009), failed to induced ethidium+
uptake. Fourth, three different P2X7 antagonists, KN-62 (Gargett and Wiley, 1997),
AZ10606120 (Michel et al., 2008) and A-438079 (Mc Garaughty et al., 2007) impaired
the ATP-induced ethidium+ uptake into KG-1 cells. Finally, the ATP- and BzATPinduced ethidium+ uptake was impaired in the presence of extracellular Na+ ions, a wellknown feature of P2X7 activation (Stevenson et al, 2009; Wiley et al, 1999). In contrast,
KG-1 cells displayed other pharmacological characteristics atypical of P2X7 activation.
First, ATP induced ethidium+ uptake at a maximal concentration of 100 μM and with an
EC50 of 8.7 μM, which is at least 3- and 10-fold lower respectively than that observed
for P2X7-mediated cation fluxes in transfected and native cells (Donnelly-Roberts et al.,
2009; Jarvis and Khakh, 2009). Second, αβ-methyl ATP, another well known non-P2X7
agonist (Jarvis and Khakh, 2009), induced partial ethidium+ uptake.
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The reason for the high potency of ATP and the partial effect of αβ-methyl ATP
resulting in the atypical pharmacological profile of P2X7 in KG-1 cells was not
established. One obvious consideration was that the ATP stock used was not prepared
properly. However a series of observations exclude this possibility. First, absorbance
measurements of the 100 mM ATP stocks confirmed that these were prepared at the
correct concentration (Pupovac, personal communication). Second, the 100 μM ATPinduced ethidium+ uptake (and cell death) was observed with two separate ATP stocks.
Third, these same ATP stocks induced ethidium+ uptake into RPMI 8226 cells with an
EC50 of 122 µM (Appendix A1.1; Pupovac and Foster, personal communication), which
is typical of recombinant P2X7 (Donnelly-Roberts et al., 2009; Jarvis and Khakh, 2009).
Another consideration was that the only used αβ-methyl ATP stock contained
contaminating

ATP.

Commercial

nucleotide

preparations

can

contain

other

contaminating nucleotides (Mahaut-Smith et al., 2000). While comparison of the
corresponding data (Fig. 5.6 and 5.7) indicate that 1 μM ATP and 100 μM αβ-methyl
ATP induced comparable amounts of ethidium+ uptake suggesting that as little as 1%
contaminating ATP of the αβ-methyl ATP stock may have contributed to the ethidium+
uptake observed with this synthetic analogue. In addition to using a second αβ-methyl
ATP stock, future studies should validate the purity of the αβ-methyl ATP (example by
high performance liquid chromatography) and the use ultra-pure αβ-methyl ATP stocks
either obtained commercially (if available) or made in-house. Nevertheless the αβmethyl ATP results do not account for the atypical results observed with ATP, which
indicates that KG-1 cells express functional P2X7 with an atypical pharmacological
profile.
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A number of reasons for the atypical pharmacological profile of P2X7 in KG-1
cells can be proposed. First, P2X7 may be able to form heteromers with P2X4 (Guo et
al., 2007) that may give rise to a receptor with P2X7-like characteristics. However the
frequency or formation of these heteromers has been recently questioned (Nicke, 2009;
Boumechache et al, 2009) and pharmacology data of these heteromers is still lacking.
Thus, this appears to be an unlikely explanation for the atypical P2X7 of KG-1 cells;
however future immunoblotting and RT-PCR studies should explore if other P2X
subtypes are present in KG-1 cells. A second explanation may be that KG-1 cells
express an alternate isoform of P2X7. A splice variant of P2X7, termed P2X7 (k),
which contains an alternate exon 1 has been observed in rats and mice, and this isoform
has increased sensitivity to ATP and BzATP (Nicke et al, 2009). Moreover, the P2X7 (k)
isoform is 77 kDa which approximates to the size of the P2X7 reactive band observed in
KG-1 cells. While the detection of the P2X7 transcript, spanning regions of exon 10 and
11, does not exclude the possibility that this transcript was the P2X7 (k) variant rather
than the more commonly observed P2X7 isoform. Future studies, should include the
potential detection of the P2X7 (k) isoform by RT-PCR. A final explanation may be that
KG-1 cells express a variant of P2X7 arising form one or more single nucleotide
polymorphisms (SNPs). A number of SNPs have been observed in the human P2RX7
gene (Fuller et al., 2009), however to the best of my knowledge none of these alter the
pharmacology of the receptor except the Arg307Gln SNP which totally ablates ATP or
BzATP binding (Gu et al, 2004). In contrast, a number of mutations have been
described which partially alter the pharmacological profile of murine P2X7 (Young et al,
2006). Future studies, should involve the complete sequencing of the P2RX7 gene in
KG-1 cells.
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ATP also induces the death of KG-1 cells by a receptor characteristic of P2X7.
As for ethidium+ uptake significant cell death was observed at 100 μM, and this effect
was greater than that observed at 1 mM ATP. Moreover, this ATP-induced cell death
was impaired by KN-62 and AZ10606120. Morphological analysis indicated that the
ATP-induced cell death was a result of apoptosis, with some cells being rounded up and
shrunken, and evidence of membrane blebbing, and fragmentation. Future, studies
should include the use of other apoptotic markers such as DNA fragmentation,
phosphatidylserine exposure, loss of membrane integrity and caspase activation to
conclusively establish that the ATP-induced KG-1 cell death is a result of apoptosis.
Previous studies have shown that the KG-1 variant cell line KG1a also expresses
functional P2X7, indicated by the presence of P2X7 protein and mRNA, and ATP- and
BzATP-induced Ca2+ fluxes (Zhang et al., 2004). Further studies by this group have
also shown that ATP and BzATP effectively inhibit cell growth which was completely
blocked by the P2X7 antagonists, KN-62 and oxidised ATP. Moreover, Zhang et al
(2009) demonstrated that ATP or BzATP induced ethidium+ uptake in sucrose but not
NaCl medium, similar in formulation to the corresponding media used in my study. In
contrast to my study however, 10- and 3-fold higher concentrations of ATP and BzATP
respectively were required to induce either YO-PRO-12+ uptake or cell death in KG1a
cells, compared to similar processes in KG-1 cells. This ability of low concentrations of
ATP to induce cell death in KG-1 cells however may be of physiological significance,
as cells are more likely to be exposed low (100 μM) rather than high (1 mM) ATP
concentrations in vivo.Therefore further studies are required to characterise the
pharmacology of P2X7 on KG1a cells as shown in this chapter.
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In contrast to KN-62 and AZ10606120, the P2X7 antagonist A-438079 (in the
absence of ATP) reduced KG-1 cell numbers as determined by the MTT assay. Of note,
A-438079 did not affect basal ethidium+ uptake into KG-1 cells (Fig. 5.8). The reason
for this effect of A438079 in the MTT assay appears to be unique to KG-1 cells, as
previous data in our laboratory has failed to observe a similar effect with this compound
in RPMI 8226 cells (Appendix A1.3) or with murine erythroleukemia cells
(Constantinescu et al, 2010). Thus, prolonged incubation (24-48 h) with A-438079
either induces KG-1 cell death or prevents KG-1 cell proliferation. Future, studies could
include the use of the trypan blue exclusion assay and morphological analysis to help
delineate between these two mechanisms. Nevertheless the mechanism seems to be
independent of P2X7 as neither KN-62 nor AZ10606120 reduced KG-1 cell numbers. It
should be noted that ATP partially prevented the effect of A-438079 on KG-1 cells.
Although these results are complicated by the cytotoxic role of ATP on KG-1 cells
(established above), they imply that ATP may be acting as a competitive inhibitor of A438079, and thus preventing A-438079 binding to its target molecule. The nature of this
target molecule remains undefined, but may include a P2 receptor present on KG-1 but
not on RPMI 8226 or MEL cells, although the species difference may also explain the
non-cytotoxic effect of A-438079 on this latter cell type.
Isatin compounds and their derivatives are known to inhibit cell proliferation and
stimulate apoptosis (Teeyapant et al., 1993; Nagle et al., 2004). Vine et al (2007)
studied the cytotoxic effect of a range of substituted isatin compounds on leukemic and
lymphoid cell lines. They found that these compounds were more sensitive to leukemic
and lymphoma cell lines as opposed to breast, prostate, and colorectal carcinoma cell
lines. The mode of action of the most potent compounds among them was characterised.
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The compound, 5,6,7-tribromoisatin, was found to be anti-proliferative and activated
the effector caspases, caspase-3 and caspase-7 in a dose-dependent manner. Romagnoli
et al (2009) more recently have characterized a novel series of alpha-bromoacryloyl Nsubstituted isatin analogues that were also found to be anti-proliferative towards the
human myeloid leukemia HL-60 and U-937 cells, as well as human lymphoid leukemia
MOLT-3 cells. These analogues caused a rapid release of cytochrome c from
mitochondria into the cytosol and subsequent caspase activation involving caspase-3, to
cleave poly(ADP-ribose) polymerase (PARP) followed by cell death. Although the
mechanisms of isatin-induced death of KG-1 cells was not fully elucidated, results in
this chapter support a role for isatin compounds in inducing death of myeloid leukemic
cells. Collectively, these findings suggest isatins are useful compounds to study
apoptotic events in cancer cells and are a potential target for anti-cancer drug
development.
In conclusion, KG-1 myeloid leukemic cells express functional P2X7 which
display an atypical pharmacological profile. Moreover activation of this receptor
mediates death of KG-1 cells. Thus KG-1 cells maybe a useful cell line model to study
atypical P2X7 and ATP-induced cell death.
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Chapter 6: General Discussion
The general aim of this project was to study the expression and function of the
P2X7 receptor in human myeloid leukemic and epithelial malignant cancer cell lines.
My study (Chapter 3) confirmed that the myeloid leukemic THP-1 cell line does not
express functional P2X7 except when differentiated with interferon-gamma (IFN-γ) and
lipopolysaccahride (LPS), as originally shown (Humphreys and Dubyak, 1998). My
study also confirmed that transforming growth factor-beta1 (TGF-β1) prevented the upregulation of P2X7 expression and function by IFN-γ and LPS in THP-1 monocytes as
previously shown (Tran, 2007; Georgiou and Sluyter, personal communication).
Subsequent data within this thesis showed that TGF-β1 prevented the up-regulation of
P2X7 by preventing P2X7 transcription and subsequent translation. Moreover, this
effect of TGF-β1 was not due to a general impairment of THP-1 cell differentiation by
IFN-γ and LPS as TGF-β1 did not prevent the up-regulation of the differentiation
markers, CD14 and MHC class II. In contrast to previous work that suggested the
presence of functional P2X7 on the epithelial colon carcinoma cell lines, HCT-8 and
Caco-2 (Coutinho-Silva et al., 2005), my study (Chapter 4) demonstrated that both these
cell lines expressed low levels of non-functional P2X7 receptors and indicated the
presence of a possible P2X7 variant. My study also established the presence of
functional P2X7 on the myeloid leukemic KG-1 cell line, but which displayed an
atypical pharmacological profile being ~10-fold more sensitive to adenosine 5’triphosphate (ATP) and sensitive to the non-P2X7 agonist, α-β-methyl adenosine 5’triphosphate (αβmeATP). Finally, my study (Chapters 3-5) also confirmed the presence
of high levels of functional P2X7 in the multiple myeloma RPMI 8226 cell line cell line
as previously observed (Farrell, 2008).
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The myeloid leukemic THP-1 cell line has become a well-established model to
study the expression and function of P2X7 following differentiation with IFN-γ and
LPS, or with 12-myristate 13-acetate (PMA) (see Section 1.3). Undifferentiated THP-1
ells however express negligible amounts of functional P2X7 (Humphreys and Dubyak,
1998; Chapter 3). On the other hand, the myeloid leukemic KG-1 cell line express low
amounts of functional P2X7, albeit with an atypical pharmacological profile, when
studied in sucrose but not NaCl medium (Section 5.1.2). Of note undifferentiated THP-1
cells express low amounts of cell-surface P2X7 and P2X7 mRNA (Section 3.1.1),
similar to that of KG-1 cells (Section 5.1.1). Thus, it will be of future interest to
determine if ATP or the most potent P2X7 agonist, BzATP, can induce ethidium+
uptake into undifferentiated THP-1 cells in sucrose medium. Conversely, given the
capacity of KG-1 cells to differentiate into macrophage-like cells (Auwerx et al., 1991;
Mary and Koeffler, 2008) or dendritic cells (Baroni et al. 2007), this cell line may be
useful in exploring the modulation of P2X7 during macrophage or dendritic cell
differentiation or in response to various inflammatory stimuli, as previously conducted
elsewhere and in my study with THP-1 cells.
The multiple myeloma RPMI 8226 cell line expresses high level of functional
P2X7 (Farrell, 2008). This cell line was used as a positive control in my study of
myeloid leukemic and epithelial colon carcinoma cell lines. Cell-surface P2X7 was ~16and ~6-fold lower on the myeloid leukemic THP-1 and KG-1 cell lines compared to the
RPMI 8226 cells (Sections 3.1.1 and 5.1.1). However, differentiation of THP-1 cells
with IFN-γ and LPS over three days raised cell-surface P2X levels, similar to those
observed in RPMI 8226 cells (Section 3.1.1 and 4.1.1). Of note however, P2X7-induced
ethidium+ uptake was ~3-fold greater in RPMI 8226 cells than in differentiated THP-1
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cells (Sections 3.1.2 and 4.1.2) despite similar amounts of cell-surface P2X7 expression.
P2RX7 genotyping, via PCR and restriction enzyme digestion (Eslick et al., 2009),
revealed that THP-1 cells but not RPMI 8226 cells are heterozygous for the Glu 496Ala
loss-of-function polymorphism (Skarratt, Farrell, Sluyter, unpublished data).

This

polymorphic variation provides the most likely explanation for the difference in P2X7
function between these two cell lines despite similar cell-surface P2X7 expression.
Similar to THP-1 and KG-1 cell lines, the epithelial colon carcinoma HCT-8 and Caco2 cell lines expressed ~9-fold less cell-surface P2X7 (Section 4.1.1) compared to RPMI
8226 cells (Section 3.1.1). Immunoblotting data (Sections 3.1.1, 4.1.1 and 5.1.1)
demonstrated that each of the cell lines expressed full-length P2X7 (75 kDa), with
amounts corresponding to amounts of cell-surface P2X7. In contrast, a potential P2X7
42 kDa variant was present in HCT-8 and Caco-2 cells (Section 4.1.1), but not in THP-1
(undifferentiated or differentiated) or KG-1 cells. This variant was postulated to be the
main cause for the consistent lack of functional P2X7 responses in both epithelial cell
lines (Section 4.2) despite extensive investigation including 3-day incubation of HCT-8
cells with IFN-γ (Section 4.1.4), which has been previously shown to up-regulate P2X7
in these cells (Welter-Stahl et al., 2009). However, as already noted for differentiated
THP-1 and RPMI 8226 cells, the presence of single nucleotide polymorphisms, which
can alter P2X7 trafficking or function (Fuller et al, 2009), provides another explanation
for the variation in P2X7 expression and function between the cell lines. Alternatively,
the variation between the cell lines studied may reflect differences in expression and
function as observed between various primary leukocyte and epithelial cell types
(Georgiou et al., 2005; Gu et al., 2000; Stevenson et al., 2009).
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APPENDIX 1

Fig. A1.1 ATP induces ethidium+ uptake in a concentration-dependant manner in RPMI
8226 cells. RPMI 8226 cells in NaCl medium, containing 25 mM ethidium+ were
incubated at 37 oC for 5 min in the presence of increasing ATP concentrations as
indicated. Incubations were stopped by addition of MgCl2 medium and centrifugation,
and the ethidium+ uptake (MFI) determined by flow cytometry. Results are shown as
mean ± SD (n = 3).
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A

B

Fig. A1.2 ATP reduces numbers of RPMI 8226 cells. RPMI 8226 cells in complete
culture medium were incubated in the absence (basal) or presence of 100 µM ATP or
200 µM BzATP at 37ºC/5%/CO2 for (A) 24 and (B) 48 hr. MTT was added during the
final 4 hr, before overnight incubation with solubilisation solution at 37ºC. Absorbances
were then read at 550 nm and 690 nm. Results are mean absorbances (A550nm- A690nm) ±
SD of (n = 3); ** P < 0.01, *** P < 0.001.
A

B

Fig. A1.3 P2X7 antagonists, KN-62 and A-438079 impair ATP-induced reduction in
RPMI 8226 cell numbers. RPMI 8226 cells in complete culture medium were preincubated at 37ºC for 15 min in (A) the presence of DMSO or 1 µM KN-62 (B)
presence of H2O or 10 µM A-438079, and (A, B) then in the absence or presence of 1
mM ATP at 37ºC/5%/CO2 for 24 hr. (A, B) MTT was added during the final 4 hr,
before overnight incubation with solubilisation solution at 37ºC. Absorbances were then
read at 550 nm and 690 nm Results are mean absorbances (A550nm- A690nm) ± SD of
triplicate wells; ***P < 0.001.
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